Document_and_Entity_Informatio
Document and Entity Information | 6 Months Ended | |
Dec. 31, 2013 | Jan. 20, 2014 | |
Entity Registrant Name | 'Cellceutix CORP | ' |
Entity Central Index Key | '0001355250 | ' |
Trading Symbol | 'ctix | ' |
Current Fiscal Year End Date | '--06-30 | ' |
Entity Filer Category | 'Accelerated Filer | ' |
Entity Common Stock, Shares Outstanding | ' | 105,877,129 |
Document Type | '10-Q | ' |
Document Period End Date | 31-Dec-13 | ' |
Amendment Flag | 'false | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q2 | ' |
CONDENSED_CONSOLIDATED_BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) | Dec. 31, 2013 | Jun. 30, 2013 |
Current Assets: | ' | ' |
Cash | $4,974,810 | $2,955,317 |
Subscription receivable | 400,000 | ' |
Prepaid expenses and security deposits | 165,154 | 4,796 |
Total Current Assets | 5,539,964 | 2,960,113 |
Other Assets: | ' | ' |
Patent costs - net | 4,649,079 | 10,400 |
Deferred offering costs | 372,626 | ' |
Total Other Assets | 5,021,705 | 10,400 |
Total Assets | 10,561,669 | 2,970,513 |
Current Liabilities: | ' | ' |
Accounts payable - (including related party payables of $1,707,576 and $1,703,916, respectively) | 1,776,863 | 1,849,077 |
Accrued expenses - (including related party accruals of $423,659 and $353,797, respectively) | 895,809 | 553,797 |
Accrued salaries and payroll taxes - (including related party accrued salaries of $3,032,500 and $3,427,294, respectively) | 3,237,697 | 3,431,018 |
Accrued settlement costs | ' | 284,519 |
Note payable - related party | 2,022,264 | 2,022,264 |
Redeemable Common Stock liability | 1,400,000 | ' |
Total Current Liabilities | 9,332,633 | 8,140,675 |
Commitments and contingencies | ' | ' |
Stockholders' Deficiency | ' | ' |
Preferred stock, $0.001 par value, 500,000 designated shares, no shares issued and outstanding | ' | ' |
Additional paid-in capital | 23,565,166 | 14,868,223 |
Deficit accumulated during the development stage | -22,346,718 | -19,773,202 |
Treasury stock - 0 and 1,382,084 shares at cost - as of December 31, 2013 and June 30, 2013, respectively | ' | -275,229 |
Total Stockholders' Equity (Deficiency) | 1,229,036 | -5,170,162 |
Total Liabilities and Stockholders' Equity (Deficiency) | 10,561,669 | 2,970,513 |
Common Class A [Member] | ' | ' |
Stockholders' Deficiency | ' | ' |
Common Stock, Value | 10,588 | ' |
Common Class B [Member] | ' | ' |
Stockholders' Deficiency | ' | ' |
Common Stock, Value | $10,046 | $0 |
CONDENSED_CONSOLIDATED_BALANCE1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) | Dec. 31, 2013 | Jun. 30, 2013 |
Accounts payable, related party payables (in dollars) | $1,707,576 | $1,703,916 |
Accrued expenses, related party accruals (in dollars) | 423,659 | 353,797 |
Accrued Salaries, due to related parties (in dollars) | $3,032,500 | $3,427,294 |
Preferred stock, par value (in dollars per share) | $0.00 | $0.00 |
Preferred stock, shares authorized (in shares) | 500,000 | 500,000 |
Preferred stock, shares issued (in shares) | ' | ' |
Preferred stock, shares outstanding (in shares) | ' | ' |
Common stock, par value (in dollars per share) | $0.00 | ' |
Common stock, shares authorized (in shares) | ' | ' |
Common stock, shares issued (in shares) | ' | ' |
Common stock, shares outstanding (in shares) | ' | ' |
Treasury stock, shares (in shares) | 0 | 1,382,084 |
Common Class A [Member] | ' | ' |
Common stock, par value (in dollars per share) | $0.00 | ' |
Common stock, shares authorized (in shares) | 300,000,000 | 300,000,000 |
Common stock, shares issued (in shares) | 105,877,129 | 100,456,068 |
Common stock, shares outstanding (in shares) | 105,877,129 | 99,073,984 |
Common Class B [Member] | ' | ' |
Number of votes entitled in class of stock (in votes) | 10 | ' |
Common stock, par value (in dollars per share) | $0.00 | $0.00 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | ' | ' |
Common stock, shares outstanding (in shares) | ' | ' |
CONDENSED_CONSOLIDATED_STATEME
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $) | 3 Months Ended | 6 Months Ended | 78 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Income Statement [Abstract] | ' | ' | ' | ' | ' |
Revenues | ' | ' | ' | ' | ' |
Operating expenses: | ' | ' | ' | ' | ' |
Research and development, gross | 1,013,570 | 281,516 | 1,585,776 | 466,469 | 8,192,669 |
Grants | ' | ' | ' | ' | -733,438 |
Research and development, net of grants | 1,013,570 | 281,516 | 1,585,776 | 466,469 | 7,459,231 |
General and administrative expenses | 225,466 | 28,267 | 329,925 | 52,287 | 1,234,557 |
Stock based compensation to employees | 105,250 | ' | 105,250 | ' | 105,250 |
Officers' payroll and payroll tax expense | 118,685 | 113,975 | 237,370 | 227,949 | 8,289,932 |
Professional fees | 83,223 | 244,573 | 206,532 | 321,888 | 3,400,412 |
Patent expense | ' | 20,409 | ' | 29,059 | 197,724 |
Total operating expenses | 1,546,194 | 688,740 | 2,464,853 | 1,097,652 | 20,687,106 |
Loss from operations | -1,546,194 | -688,740 | -2,464,853 | -1,097,652 | -20,687,106 |
Other income (expenses) | ' | ' | ' | ' | ' |
Interest income | 261 | ' | 432 | ' | 432 |
Interest expense | 50,557 | 60,080 | 109,095 | 120,160 | 933,585 |
Loss on financial instruments | ' | ' | ' | ' | -439,892 |
Total other expenses | -50,296 | -60,080 | -108,663 | -120,160 | -1,373,045 |
Net loss before provision for income taxes | -1,596,490 | -748,820 | -2,573,516 | -1,217,812 | -22,060,151 |
Provision for income taxes | ' | ' | ' | ' | ' |
Net loss | -1,596,490 | -748,820 | -2,573,516 | -1,217,812 | -22,060,151 |
Deemed dividends | 1,979,706 | ' | 1,979,706 | 211,802 | 2,257,194 |
Net loss attributable to common stockholders | ($3,576,196) | ($748,820) | ($4,553,222) | ($1,429,614) | ($24,317,345) |
Basic and diluted loss per share attributable to common stockholders (in dollars per share) | ($0.03) | ($0.01) | ($0.04) | ($0.02) | ' |
Weighted average number of common shares (in shares) | 104,640,788 | 93,507,421 | 102,659,696 | 93,001,981 | ' |
CONSOLIDATED_STATEMENTS_OF_STO
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $) | Preferred Stock | Common Stock | Additional Paid-in Capital | Deficit Accumulated During Development Stage | Treasury Stock | Total |
Balance at Jun. 30, 2007 | ' | $100 | ' | ($530) | ' | ($430) |
Balance (in shares) at Jun. 30, 2007 | ' | 1,000,000 | ' | ' | ' | ' |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ' | ' | ' | ' | ' | ' |
Share exchange with Cellceutix Pharma, Inc. | ' | -100 | ' | 100 | ' | ' |
Share exchange with Cellceutix Pharma, Inc. (in shares) | ' | -1,000,000 | ' | ' | ' | ' |
Share exchange in reverse merger with Cellceutix Pharma, Inc | ' | 8,200 | ' | -8,200 | ' | ' |
Share exchange in reverse merger with Cellceutix Pharma, Inc (in shares) | ' | 82,000,000 | ' | ' | ' | ' |
Shares exchanged in a reverse acquisition of Cellceutix Pharma, Inc. (December) | ' | 979 | ' | -979 | ' | ' |
Shares exchanged in a reverse acquisition of Cellceutix Pharma, Inc. (December) (in shares) | ' | 9,791,000 | ' | ' | ' | ' |
Forgiveness of debt from a stockholder | ' | ' | 50 | ' | ' | 50 |
Capital contribution from a stockholder | ' | ' | 50 | ' | ' | 50 |
Issuance of stock options | ' | ' | 43,533 | ' | ' | 43,533 |
Shares issued for services | ' | 10 | 104,990 | ' | ' | ' |
Shares issued for services (in shares) | ' | 100,000 | ' | ' | ' | ' |
Net loss | ' | ' | ' | -510,193 | ' | -510,193 |
Balance at Jun. 30, 2008 | ' | 9,189 | 148,623 | -519,802 | ' | -361,990 |
Balance (in shares) at Jun. 30, 2008 | ' | 91,891,000 | ' | ' | ' | ' |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ' | ' | ' | ' | ' | ' |
Cancellation of shares issued for services | ' | -10 | -104,990 | ' | ' | ' |
Cancellation of shares issued for services (in shares) | ' | -100,000 | ' | ' | ' | ' |
Issuance of stock options | ' | ' | 142,162 | ' | ' | 142,162 |
Shares issued for services | ' | 2 | 7,598 | ' | ' | ' |
Shares issued for services (in shares) | ' | 20,000 | ' | ' | ' | ' |
Shares issued for services | ' | 3 | 9,497 | ' | ' | ' |
Shares issued for services (in shares) | ' | 25,000 | ' | ' | ' | ' |
Net loss | ' | ' | ' | -1,485,331 | ' | -1,485,331 |
Balance at Jun. 30, 2009 | ' | 9,184 | 202,890 | -2,005,133 | ' | -1,793,059 |
Balance (in shares) at Jun. 30, 2009 | ' | 91,836,000 | ' | ' | ' | ' |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ' | ' | ' | ' | ' | ' |
Issuance of stock options | ' | ' | 383,291 | ' | ' | 383,291 |
Shares issued for services | ' | 2 | 1,050 | ' | ' | ' |
Shares issued for services (in shares) | ' | 3,500 | ' | ' | ' | ' |
Shares issued for services | ' | 8 | 33,742 | ' | ' | 33,750 |
Shares issued for services (in shares) | ' | 75,000 | ' | ' | ' | ' |
Net loss | ' | ' | ' | -3,433,400 | ' | -3,433,400 |
Balance at Jun. 30, 2010 | ' | 9,194 | 631,721 | -5,438,533 | ' | -4,797,618 |
Balance (in shares) at Jun. 30, 2010 | ' | 91,939,500 | ' | ' | ' | ' |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ' | ' | ' | ' | ' | ' |
Forgiveness of debt from a stockholder | ' | ' | 932,966 | ' | ' | 932,966 |
Cancellation of shares issued | ' | -8 | -33,742 | ' | ' | -33,750 |
Cancellation of shares issued (in shares) | ' | -75,000 | ' | ' | ' | ' |
Modification of stock options | ' | ' | 237,098 | ' | ' | 237,098 |
Repurchase of common stock in connection with settlement | ' | ' | ' | ' | -859,388 | -859,388 |
Repurchase of common stock in connection with settlement (in shares) | ' | ' | ' | ' | 4,602,313 | ' |
Issuance of stock options | ' | ' | 3,060,691 | ' | ' | 3,060,691 |
Shares issued for services | ' | 1 | 9,719 | ' | ' | ' |
Shares issued for services (in shares) | ' | 12,000 | ' | ' | ' | ' |
Shares issued for services | ' | 18 | 58,982 | ' | ' | 59,000 |
Shares issued for services (in shares) | ' | 184,375 | ' | ' | ' | ' |
Cancellation of treasury stock | ' | -45 | -99,955 | ' | 100,000 | ' |
Cancellation of treasury stock (in shares) | ' | -460,229 | ' | ' | -460,229 | ' |
Net loss | ' | ' | ' | -5,938,297 | ' | -5,938,297 |
Balance at Jun. 30, 2011 | ' | 9,172 | 4,838,968 | -11,376,830 | -759,388 | -7,288,078 |
Balance (in shares) at Jun. 30, 2011 | ' | 91,720,646 | ' | ' | 4,142,084 | ' |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ' | ' | ' | ' | ' | ' |
Convertible Debentures converted to common stock | ' | 71 | 353,564 | ' | ' | 353,635 |
Convertible debentures converted to common stock (in shares) | ' | 707,277 | ' | ' | ' | ' |
Issuance of stock options | ' | ' | 2,114,386 | ' | ' | 2,114,386 |
Shares issued for charitable contributions | ' | 26 | 137,894 | ' | ' | ' |
Shares issued for charitable contributions (in shares) | ' | 265,228 | ' | ' | ' | ' |
Shares issued for services | ' | 13 | 51,236 | ' | ' | ' |
Shares issued for services (in shares) | ' | 125,000 | ' | ' | ' | ' |
Shares issued for services | ' | 2 | 13,248 | ' | ' | ' |
Shares issued for services (in shares) | ' | 25,000 | ' | ' | ' | ' |
Issuance of capital stock | ' | 250 | 582,143 | ' | ' | 582,393 |
Issuance of capital stock (in shares) | ' | 2,500,000 | ' | ' | ' | ' |
Reclassification of warrants into equity | ' | ' | 857,500 | ' | ' | 857,500 |
Cancellation of treasury stock | ' | -138 | -231,517 | ' | 231,655 | ' |
Cancellation of treasury stock (in shares) | ' | -1,380,000 | ' | ' | -1,380,000 | ' |
Issuance of preferred stock | 10 | ' | 99,990 | ' | ' | 100,000 |
Issuance of preferred stock (in shares) | 10,000 | ' | ' | ' | ' | ' |
Deemed dividend's | ' | ' | 65,686 | -65,686 | ' | ' |
Conversion of preferred stock to common stock | -10 | 26 | -16 | ' | ' | ' |
Conversion of preferred stock to common stock (in shares) | -10,000 | 255,754 | ' | ' | ' | ' |
Net loss | ' | ' | ' | -4,894,402 | ' | -4,894,402 |
Balance at Jun. 30, 2012 | ' | 9,497 | 9,229,157 | -16,336,918 | -527,733 | -7,625,997 |
Balance (in shares) at Jun. 30, 2012 | ' | 94,968,905 | ' | ' | 2,762,084 | ' |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ' | ' | ' | ' | ' | ' |
Issuance of stock options | ' | ' | 217,047 | ' | ' | 217,047 |
Shares issued for charitable contributions | ' | 10 | 219,990 | ' | ' | ' |
Shares issued for charitable contributions (in shares) | ' | 100,000 | ' | ' | ' | ' |
Shares issued for services | ' | 5 | 43,495 | ' | ' | ' |
Shares issued for services (in shares) | ' | 50,000 | ' | ' | ' | ' |
Shares issued for services | ' | 1 | 8,899 | ' | ' | 8,900 |
Shares issued for services (in shares) | ' | 5,000 | ' | ' | ' | ' |
Shares issued as commitment fee | ' | 34 | 299,967 | ' | ' | ' |
Shares issued as commitment fee (in shares) | ' | 336,625 | ' | ' | ' | ' |
Shares sold at net of offering costs | ' | 160 | 2,682,957 | ' | ' | 2,683,117 |
Shares sold at net of offering costs (in shares) | ' | 1,600,000 | ' | ' | ' | ' |
Offering cost | ' | ' | -168,528 | ' | ' | -168,528 |
Exercise of stock options | ' | 225 | 278,225 | ' | ' | 278,450 |
Exercise of stock options (in shares) | ' | 2,255,000 | ' | ' | ' | ' |
Exercise of warrants | ' | 74 | 185,176 | ' | ' | 185,250 |
Exercise of warrants (in shares) | ' | 741,000 | ' | ' | ' | ' |
Cancellation of treasury stock | ' | -138 | -252,366 | ' | 252,504 | ' |
Cancellation of treasury stock (in shares) | ' | -1,380,000 | ' | ' | -1,380,000 | ' |
Issuance of preferred stock | 30 | ' | 299,970 | ' | ' | 300,000 |
Issuance of preferred stock (in shares) | 30,000 | ' | ' | ' | ' | ' |
Deemed dividend's | ' | ' | 211,802 | -211,802 | ' | ' |
Conversion of preferred stock to common stock | -30 | 59 | -29 | ' | ' | ' |
Conversion of preferred stock to common stock (in shares) | -30,000 | 592,330 | ' | ' | ' | ' |
Net loss | ' | ' | ' | -3,224,482 | ' | -3,224,482 |
Balance at Jun. 30, 2013 | ' | 10,046 | 14,868,223 | -19,773,202 | -275,229 | -5,170,162 |
Balance (in shares) at Jun. 30, 2013 | ' | 100,456,068 | ' | ' | 1,382,084 | ' |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ' | ' | ' | ' | ' | ' |
Issuance of stock options | ' | ' | 45,758 | ' | ' | 45,758 |
Exercise of warrants | ' | 102 | 1,024,898 | ' | ' | 1,025,000 |
Exercise of warrants (in shares) | ' | 1,025,000 | ' | ' | ' | ' |
Cancellation of treasury stock | ' | -138 | -275,091 | ' | 275,229 | ' |
Cancellation of treasury stock (in shares) | ' | -1,382,083 | ' | ' | 1,382,084 | ' |
Shares sold in July, 2013 to Sep, 2013 at $1.66-$1.94 | ' | 210 | 3,730,130 | ' | ' | 3,730,340 |
Shares sold in July, 2013 to Sep, 2013 at $1.66-$1.94 | ' | 2,100,000 | ' | ' | ' | ' |
Shares issued to shareholder of Polymedix at $1.93 | ' | 140 | 1,301,860 | ' | ' | 1,302,000 |
Shares issued to shareholder of Polymedix at $1.93 (in shares) | ' | 1,400,000 | ' | ' | ' | ' |
Net loss | ' | ' | -2,573,516 | ' | ' | -2,573,516 |
Balance at Dec. 31, 2013 | ' | $10,588 | $23,565,166 | ($22,346,718) | ' | $1,229,036 |
Balance (in shares) at Dec. 31, 2013 | ' | 105,877,129 | ' | ' | ' | ' |
CONSOLIDATED_STATEMENTS_OF_STO1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (USD $) | 6 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||
Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Jun. 30, 2013 | Jun. 30, 2013 | Jun. 30, 2013 | Jun. 30, 2013 | Jun. 30, 2012 | Jun. 30, 2011 | Jun. 30, 2013 | Jun. 30, 2013 | Jun. 30, 2013 | Jun. 30, 2013 | Jun. 30, 2012 | Jun. 30, 2011 | Jun. 30, 2013 | Jun. 30, 2013 | Jun. 30, 2012 | Jun. 30, 2013 | Jun. 30, 2012 | Jun. 30, 2010 | Jun. 30, 2009 | Jun. 30, 2013 | Jun. 30, 2011 | Jun. 30, 2010 | Jun. 30, 2011 | Jun. 30, 2010 | Jun. 30, 2012 | Jun. 30, 2008 | Jun. 30, 2012 | Jun. 30, 2012 | |
October to December | October to December | July To September | July To September | May And June | May And June | May And June | March | March | March | March | March | December | May | May | May | October | August | August | June | June | June | June | July | July | July | February | February | April | April | January | November | ||
Maximum | Minimum | Maximum | Minimum | Maximum | Minimum | Maximum | Minimum | ||||||||||||||||||||||||||
Shares issued, price per share for services (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.32 | ' | ' | ' | ' | $0.49 | $0.81 | $0.87 | $0.60 | $0.38 | $1.78 | $0.62 | $0.45 | $0.38 | $0.59 | $0.55 | $0.43 | $0.20 | $0.30 | $0.46 | $1.05 | $0.45 | $0.41 |
Shares issued, price per share for services (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.53 | ' | ' | ' | ' | ' | ' | ' | $0.38 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share issued, price per share charitable contributions (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.52 | ' | ' | ' | ' | $2.20 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares issued, price per share for commitment fee (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.89 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares issued, price per share at net offering cost (in dollars per share) | ' | ' | ' | ' | ' | ' | $1.97 | $1.58 | ' | ' | ' | $1.54 | $1.45 | $0.89 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Offering costs on share issue | ' | ' | ' | ' | ' | $82,983 | ' | ' | $45,490 | ' | ' | ' | ' | $3,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares sold, price per share (in dollars per share) | ' | $1.78 | $1.66 | $1.94 | $1.66 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares issued, price per share for acquisition (in dollars per share) | $1.93 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares issued, employees for bonus (in dollar per share) | ' | $1.85 | $1.60 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares issued, employees for bonus (shares) | ' | 60,000 | 5,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares issued, consultants (in dollar per share) | $2.09 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares issued, offering cost (in dollar per share) | $1.77 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
CONDENSED_CONSOLIDATED_STATEME1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $) | 6 Months Ended | 78 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ' | ' | ' |
Net loss | ($2,573,516) | ($1,217,812) | ($22,060,151) |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' | ' |
Loss on disposal of fixed assets | 72,400 | ' | 72,400 |
Common stock and stock options issued as payment for services compensation, services rendered, and charitable contributions and financing costs | 255,508 | 214,165 | 7,464,073 |
Cancellation of stock issued for services | ' | ' | -28,750 |
Amortization of accrued settlement costs | ' | 18,215 | 125,131 |
Amortization of patent costs | 101,844 | 501 | 102,460 |
Loss on financial instruments | ' | ' | 439,892 |
Changes in operating assets and liabilities: | ' | ' | ' |
Prepaid expenses | 160,358 | 11,879 | 156,669 |
Accounts payable | -72,214 | 21,977 | 1,776,912 |
Accrued expenses | 342,012 | 81,688 | 1,127,970 |
Accrued officers' salaries and payroll taxes | -193,321 | 414,452 | 4,170,662 |
Net cash used in operating activities | -2,227,645 | -478,693 | -6,966,070 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ' | ' | ' |
Proceeds from disposal of fixed assets | 23,600 | ' | 23,600 |
Patent Costs | 2,134,523 | 3,348 | 2,145,539 |
Net cash used in investing activities | -2,110,923 | -3,348 | -2,121,939 |
CASH FLOWS FROM FINANCING ACTIVITIES: | ' | ' | ' |
Capital contribution from stockholder | ' | ' | 50 |
Sale of common stock and preferred stock | 5,617,580 | 100,000 | 10,000,100 |
Sale of preferred stock | ' | 300,000 | 400,000 |
Payment of settlement liabilities | -284,519 | ' | -984,519 |
Loan from officer | ' | ' | 1,925,587 |
Proceeds from convertible debentures | ' | ' | -167,099 |
Redemption of convertible debentures | ' | ' | 400,000 |
Proceeds from subscription | ' | 277,200 | 1,000,000 |
Exercise of stock options and warrants | 1,025,000 | ' | 1,488,700 |
Net cash provided by financing activities | 6,358,061 | 677,200 | 14,062,819 |
NET INCREASE IN CASH AND CASH EQUIVALENTS | 2,019,493 | 195,159 | 4,974,810 |
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | 2,955,317 | 27,703 | ' |
CASH AND CASH EQUIVALENTS, END OF PERIOD | 4,974,810 | 222,862 | 4,974,810 |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ' | ' | ' |
Cash paid for interest | 37,433 | 25,909 | 343,462 |
SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW FINANCING ACTIVITIES | ' | ' | ' |
Common stock issued for acquisition | ' | ' | 9,079 |
Forgiveness of debt | ' | ' | 50 |
Reclassification of accrued interest to note payable and convertible debentures | ' | ' | 197,964 |
Cancellation of common stock for services | ' | ' | -138,750 |
Settlement of accrued payroll and payroll taxes | ' | ' | 932,966 |
Cancellation of common stock as a result of settlement | ' | ' | 859,388 |
Debt converted to common stock | ' | ' | 353,635 |
Cancellation of treasury stock | -275,229 | ' | -759,388 |
Reclassification of warrants to equity | ' | ' | 857,500 |
Deemed dividend from beneficial conversion feature on preferred stock | ' | 53,032 | 70,678 |
Deemed dividend - warrants | 1,979,706 | 158,770 | 2,186,516 |
Conversion of preferred stock into common stock | ' | -30 | -46 |
Shares issued as deferred offering costs | 372,605 | ' | 672,606 |
Shares issued for acquisition of patent and equipment | 2,702,000 | ' | 2,702,000 |
Redeemable Common Stock liability | 1,400,000 | ' | 1,400,000 |
Stock subscription receivable | $400,000 | ' | $400,000 |
Basis_of_Presentation_and_Natu
Basis of Presentation and Nature of Operations | 6 Months Ended |
Dec. 31, 2013 | |
Accounting Policies [Abstract] | ' |
Basis of Presentation and Nature of Operations | ' |
1. Basis of Presentation and Nature of Operations | |
Basis of Presentation | |
The accompanying unaudited condensed consolidated financial statements of Cellceutix Corporation have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive consolidated financial statements and should be read in conjunction with our audited financial statements for the year ended June 30, 2013, included in our Annual Report on Form 10-K for the year ended June 30, 2013. | |
In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. When used in these notes, the terms "Company", "we", "us" or "our" mean Cellceutix Corporation. | |
Cellceutix Corporation, formerly known as EconoShare, Inc., (“Cellceutix” or the “Company”) was incorporated on August 1, 2005. On December 6, 2007, the Company acquired Cellceutix Pharma, Inc. which was incorporated in the State of Delaware on June 20, 2007, in exchange for newly issued shares of the Company’s common stock. As a result of the exchange, Cellceutix Pharma, Inc. became a wholly-owned subsidiary of the Company. The Company is a clinical stage biopharmaceutical company and has no customers, products or revenues to date. Accordingly, the accompanying financial statements have been prepared in accordance with generally accepted accounting principles related to development-stage companies as set forth in Financial Accounting Standards Board Accounting Standards Codification 915 (“FASB ASC 915”). A development-stage company is one in which planned principal operations have not commenced or if its operations have commenced, there has been no significant revenues there from. | |
The Company’s Common Stock is quoted on the Over the Counter Bulletin Board (OTCBB), symbol “CTIX”. | |
All amounts, where it is designated in these notes to the financial statements as an approximate amount, are rounded to the nearest thousand dollars. | |
Nature of Operations | |
Overview | |
We are in the business of developing innovative small molecule therapies to treat diseases with significant medical need, particularly in the areas of cancer and inflammatory disease. Our strategy is to use our business and scientific expertise to maximize the value of our pipeline. We will do this by focusing on our lead compounds, Kevetrin, Prurisol and Brilacidin, and advancing them as quickly as possible along the regulatory pathway. We will develop the highest quality data and broadest intellectual property to support our compounds. | |
We currently own all development and marketing rights to our products. In order to successfully develop and market our products, we may have to partner with other companies. Prospective partners may require that we grant them significant development and/or commercialization rights in return for agreeing to share the risk of development and/or commercialization. |
Going_Concern
Going Concern | 6 Months Ended |
Dec. 31, 2013 | |
Going Concern [Abstract] | ' |
Going Concern | ' |
2. Going Concern | |
The accompanying financial statements have been prepared assuming the Company will continue as a going concern. For the period since June 20, 2007 (date of inception) through December 31, 2013, the Company has had a cumulative net loss attributable to common stockholders of $22.3 million and a working capital deficit of $3.8 million at December 31, 2013. As of December 31, 2013, the Company has not emerged from the development stage. In view of these matters, the ability of the Company to continue as a going concern is dependent upon the Company’s ability to generate additional financing. Since inception, the Company has financed its activities principally from the use of equity securities, debt issuance and loans from an officer to pay for its operations. The Company intends on financing its future development activities and its working capital needs largely from the issuance of debt and the sale of equity securities, until such time that funds provided by operations are sufficient to fund working capital requirements. On October 25, 2013, we terminated a previous agreement with Aspire Capital Fund, LLC, an Illinois limited liability company (Aspire Capital), and entered into a new stock purchase agreement (the “Purchase Agreement”) with Aspire Capital. | |
The Purchase Agreement provides that upon meeting the terms of the agreement, Aspire Capital is committed to purchase up to an aggregate of $20,000,000 of our shares of Class A Common Stock over the approximately 36-month term of the Purchase Agreement. In consideration for entering into the Purchase Agreement, the Company issued to Aspire Capital 210,523 shares of our Class A Common Stock as a commitment fee. The commitment fee will be amortized as the funding is received. The unamortized portion is carried on the balance sheet as deferred offering costs. Concurrently with entering into the Purchase Agreement, the Company agreed to file one or more registration statements as permissible and necessary under the Securities Act of 1933, as amended, or the Securities Act, for the sale of shares of our Class A Common Stock that have been and may be issued to Aspire Capital under the Purchase Agreement. On November 4, 2013, the Company filed a Form S-3 registration statement and the registration statement was declared effective by the SEC on November 15, 2013. | |
These factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of liabilities that may be necessary should the Company be unable to continue as a going concern. |
Significant_Accounting_Policie
Significant Accounting Policies and Recent Accounting Pronouncements | 6 Months Ended | ||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||||||
Significant Accounting Policies and Recent Accounting Pronouncements | ' | ||||||||||||||||||||
3. Significant Accounting Policies and Recent Accounting Pronouncements | |||||||||||||||||||||
Cash and Cash Equivalents | |||||||||||||||||||||
Cash and cash equivalents consist of cash and short-term highly liquid investments purchased with original maturities of three months or less. There were no cash equivalents at December 31, 2013 and June 30, 2013. | |||||||||||||||||||||
Intangible Assets – Patents | |||||||||||||||||||||
Costs incurred to file patent applications and acquired intangibles are capitalized when the Company believes that there is a high likelihood that the patent will issue and there will be future economic benefit associated with the patent. These costs will be amortized on a straight-line basis over a 12 - 17 years life from the date of patent filing. All costs associated with abandoned patent applications are expensed. In addition, the Company will review the carrying value of patents for indicators of impairment on a periodic basis and if it determines that the carrying value is impaired, it values the patent at fair value. Costs incurred to file patent applications and acquire intangibles are expensed when the patents have failed to develop products which have gained market acceptance. For the three months ended December 31, 2013 and 2012, the Company has charged to operations approximately $0 and $20,000, respectively for these patent application costs. For the six months ended December 31, 2013 and 2012 and from inception to December 31, 2013, the Company has charged to operations $0, $29,000, and $197,000, respectively for these patent application costs | |||||||||||||||||||||
In accordance with the provisions of the applicable authoritative guidance, the Company’s long-lived assets and amortizable intangible assets are tested for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. The Company assesses the recoverability of such assets by determining whether their carrying value can be recovered through undiscounted future operating cash flows, including its estimates of revenue driven by assumed market segment share and estimated costs. If impairment is indicated, the Company measures the amount of such impairment by comparing the fair value to the carrying value. During the three and six months ended December 31, 2013 and 2012, no impairment was recorded. | |||||||||||||||||||||
Financial Instruments | |||||||||||||||||||||
The Company’s financial instruments include cash, accounts payable and accrued liabilities. The carrying amounts of these financial instruments approximate their fair value, due to the short-term nature of these items. | |||||||||||||||||||||
Use of Estimates | |||||||||||||||||||||
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |||||||||||||||||||||
Significant Estimates | |||||||||||||||||||||
These accompanying consolidated financial statements include some amounts that are based on management’s best estimates and judgments. The most significant estimates relate to valuation of stock grants and stock options, valuation of purchased intangibles and the valuation allowance on deferred tax assets. It is reasonably possible that these above-mentioned estimates and others may be adjusted as more current information becomes available, and any adjustment could be significant in future reporting periods. | |||||||||||||||||||||
Certain Risks and Uncertainties | |||||||||||||||||||||
Product Development | |||||||||||||||||||||
We devote significant resources to research and development programs in an effort to discover and develop potential future product candidates. The product candidates in our pipeline are at various stages of preclinical and clinical development. The path to regulatory approval includes three phases of clinical trials in which we collect data to support an application to regulatory authorities to allow us to market a product for treatment of a specified disease. There are many difficulties and uncertainties inherent in research and development of new products, resulting in a high rate of failure. To bring a drug from the discovery phase to regulatory approval, and ultimately to market, takes many years and significant cost. Failure can occur at any point in the process, including after the product is approved, based on post-market factors. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain necessary regulatory approvals, limited scope of approved uses, reimbursement challenges, difficulty or excessive costs of manufacture, alternative therapies or infringement of the patents or intellectual property rights of others. Uncertainties in the FDA approval process and the approval processes in other countries can result in delays in product launches and lost market opportunities. Consequently, it is very difficult to predict which products will ultimately be submitted for approval, which have the highest likelihood of obtaining approval and which will be commercially viable and generate profits. Successful results in preclinical or clinical studies may not be an accurate predictor of the ultimate safety or effectiveness of a drug or product candidate. | |||||||||||||||||||||
Expenditures for research, development, and engineering of products are expensed as incurred. In November 2010, the Company was awarded three separate U.S. government grants under the Qualifying Therapeutic Discovery Project (QTDP) program. For the period from inception to December 31, 2013, the Company has reflected $733,438 of grants as a one time reduction of research and development expenses. For the three months ended December 31, 2013 and 2012, and the period from inception to December 31, 2013, the Company incurred approximately $1,014,000 and $282,000of research and development costs, net of grants respectively. For the six months ended December 31, 2013 and 2012, and the period from inception to December 31, 2013, the Company incurred approximately $1,586,000, $466,000, and $7,459,000 of research and development costs, net of grants respectively. | |||||||||||||||||||||
Concentrations of Credit Risk | |||||||||||||||||||||
All cash is maintained with a major financial institution in the United States. Deposits with this bank may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. | |||||||||||||||||||||
Income Taxes | |||||||||||||||||||||
Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. | |||||||||||||||||||||
The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes. The deferred tax assets were primarily comprised of federal and state tax net operating loss, or NOL, carryforwards. Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these tax assets, a full valuation allowance has been established to offset the deferred tax assets. Additionally, the future utilization of the NOL carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that could occur in the future. If necessary, the deferred tax assets will be reduced by any carryforwards that expire prior to utilization as a result of such limitations, with a corresponding reduction of the valuation allowance. | |||||||||||||||||||||
The Company follows the provisions of FASB ASC 740-10 "Uncertainty in Income Taxes" (ASC 740-10). The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. | |||||||||||||||||||||
The Company has identified its U.S. Federal income tax return and its State return in Massachusetts as its major tax jurisdictions. The fiscal 2011 and forward years are still open for examination. | |||||||||||||||||||||
Basic Earnings (Loss) per Share | |||||||||||||||||||||
Basic and diluted earnings per share are computed based on the weighted-average common shares and common share equivalents outstanding during the period. Common share equivalents consist of stock options, warrants and convertible notes payable. Common share equivalents of approximately 47.6 million and 50 million were excluded from the computation of diluted earnings per share as of December 31, 2013 and 2012, respectively, have been excluded from the per share computations for the three and six months ended December 31, 2013 and 2012, because their effect is anti-dilutive. | |||||||||||||||||||||
Accounting for Stock Based Compensation | |||||||||||||||||||||
The stock-based compensation expense incurred by Cellceutix for employees and directors in connection with its stock option plan is based on the employee model of ASC 718, and the fair market value of the options is measured at the grant date. Under ASC 718 employee is defined as “An individual over whom the grantor of a share-based compensation award exercises or has the right to exercise sufficient control to establish an employer-employee relationship based on common law as illustrated in case law and currently under U.S.“tax regulations”. Our consultants do not meet the employer-employee relationship as defined by the IRS and therefore are accounted for under ASC 505-50. | |||||||||||||||||||||
ASC 505-50-30-11 (previously EITF 96-18) further provides that an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: | |||||||||||||||||||||
i. | The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and | ||||||||||||||||||||
ii. | The date at which the counterparty’s performance is complete. | ||||||||||||||||||||
We have elected to use the Black-Scholes-Merton pricing model to determine the fair value of stock options on the dates of grant. Restricted stock units are measured based on the fair market values of the underlying stock on the dates of grant. We recognize stock-based compensation using the straight-line method. | |||||||||||||||||||||
The components of stock based compensation related to stock options recognized in the Company’s Statement of Operations for the three and six months ended December 31, 2013 and 2012 and since inception are as follows(rounded to nearest thousand): | |||||||||||||||||||||
Three Months Ended December 31, 2013 | Three Months Ended December 31, 2012 | Six Months Ended December 31, 2012 | For the cumulative period from June 20, 2007 (Date of Inception) through December 31, 2013 | ||||||||||||||||||
Six Months Ended December 31, 2013 | |||||||||||||||||||||
Employee’s stock compensation | $ | 105,000 | $ | - | $ | 105,000 | $ | - | $ | 105,000 | |||||||||||
Officers’ stock compensation | - | - | - | - | 4,850,000 | ||||||||||||||||
Consulting | 124,000 | 138,000 | 150,000 | 214,000 | 1,617,000 | ||||||||||||||||
Patent expense | - | - | - | - | 19,000 | ||||||||||||||||
Total | $ | 229,000 | $ | 138,000 | $ | 255,000 | $ | 214,000 | $ | 6,591,000 | |||||||||||
Recent Accounting Pronouncements | |||||||||||||||||||||
The Company has reviewed all recent accounting pronouncements issued by FASB (including EITF), the AICPA and the SEC and did not or are not believed by management to have a material impact on the Company’s present or future financial statements. |
Polymedix_Inc_Asset_Acquisitio
Polymedix Inc. Asset Acquisition Patent Rights and Equipment | 6 Months Ended | ||||
Dec. 31, 2013 | |||||
Business Combinations [Abstract] | ' | ||||
Polymedix Inc. Asset Acquisition -Patent Rights and Equipment | ' | ||||
4. Polymedix Inc. Asset Acquisition –Patent Rights and Equipment | |||||
On September 4, 2013, the Company purchased substantially all of the assets (“Purchased Assets”) of Polymedix Inc, and Polymedix Pharmaceuticals, Inc. (“Seller”) from the U.S. Bankruptcy Court. | |||||
The aggregate purchase price for the sale and transfer of the Purchased Assets was $2.1 million in cash, plus 1.4 million shares of the Company’s Class A common stock (the “Registrable Securities”), for a total aggregate purchase price of approximately $4.8 million. These common shares were valued at $1.93 per share, based on the September 4, 2013 opening stock price as quoted on the OTB Bulletin Board, resulting in approximately $2.7 million of stock issued to acquire the Purchased Assets. The Purchased Assets Agreement also provides the Seller with the right to require the Company to redeem the Common Stock held by such Seller (the “Put Option”) at any time between one day after the closing and three hundred and sixty-five days after the closing, the seller or any holder of the registrable securities may make written demand upon the purchase for the purchase to repurchase the registrable securities for $1 per share. | |||||
Because the Company is required to repurchase these issued common shares if the Seller exercises the above Put Option, this redemption feature meets the definition under the ASC 480-10-25-8, “Obligations to Repurchase Issuer’s Equity Shares by Transferring Assets”. Per ASC 480-10-25-8, the obligation to repurchase an issuer’s own shares by transferring assets should be recognized as a liability at inception date. Therefore, the number of potential shares needed to repurchase the Common Stock under this Put Option was 1,400,000 shares as of December 31, 2013. This obligation was recorded as a current liability of $1.4 million of Redeemable Common Stock liability in the accompanying balance sheet. | |||||
ASC 805, Business Combinations, provides guidance on determining whether an acquired set of assets meets the definition of a business for accounting purposes. Under the framework, the acquired set of activities and assets have to be capable of being operated as a business, from the viewpoint of a market participant as defined in ASC 820, Fair Value Measurements. Two essential elements required for an integrated set of activities are inputs and outputs. The Company evaluated the Asset Purchase Agreement and in accordance with the guidance, determined it did not meet the definition of a business acquisition as the acquisition consisted solely of the two primary compounds, Brilacidin and related compounds, and Delparantag and related compounds, and certain other tangible assets. The Company did not acquire the right to any employees previously involved with the technology, or research processes previously in place at Seller. The Company has therefore accounted for the transaction as an asset acquisition. | |||||
The purchase price was allocated to the identified tangible and intangible assets acquired based on their relative fair values, which were derived from their individual estimated fair values of $96,000 and $4,706,000, respectively. | |||||
The following table summarizes the purchase price allocation for the assets acquired: | |||||
Intangible assets – patents rights – Brilacidin, Delparantag and other related compounds | $ | 4,706,000 | |||
Tangible assets - Laboratory equipment and computer systems | $ | 96,000 | |||
These tangible assets of $96,000 acquired were expensed to research and development costs in September 2013. |
Patents_net
Patents, net | 6 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | ||||||||||||
Patents, net | ' | ||||||||||||
5. Patents, net | |||||||||||||
Patents, net consisted of the following (rounded to nearest thousand): | |||||||||||||
Useful life | 31-Dec-13 | 30-Jun-13 | |||||||||||
Purchased Patent Rights– Brilacidin, and related compounds (note 4) | 14 | $ | 4,082,000 | $ | - | ||||||||
Purchased Patent Rights–Delparantag and related compounds (note 4) | 12 | 480,000 | - | ||||||||||
Purchased Patent Rights–Anti-microbial- surfactants and related compounds (note 4) | 12 | 144,000 | - | ||||||||||
Patents – Kevetrin and related compounds | 17 | 45,000 | 11,000 | ||||||||||
$ | 4,751,000 | $ | 11,000 | ||||||||||
Accumulated amortization | 102,000 | 1,000 | |||||||||||
$ | 4,649,000 | $ | 10,000 | ||||||||||
The patents are amortized on a straight-line basis over the estimated remaining useful lives of the assets, determined 12-17 years from the date of acquisition. | |||||||||||||
Amortization expense for the three and six months ended December 31, 2013 and 2012 and from inception to December 31, 2013 was approximately $80,000 $0, $102,000, $0, and $102,000, respectively. At December 31, 2013, the amortization period for all patents was approximately 11.50 to 16.50 years. Future estimated annual amortization expense is $316,000 for years from 2014 to 2028, and $3,000 for the year 2029. |
Accrued_Expenses
Accrued Expenses | 6 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Accrued Expenses [Abstract] | ' | ||||||||
Accrued Expenses | ' | ||||||||
6. Accrued Expenses | |||||||||
Accrued expenses consisted of the following (rounded to nearest thousand): | |||||||||
31-Dec-13 | 30-Jun-13 | ||||||||
Accrued research and development consulting fees | $ | 459,000 | $ | 200,000 | |||||
Accrued rent – related parties | 59,000 | 60,000 | |||||||
Accrued interest – related parties | 365,000 | 294,000 | |||||||
Others | 13,000 | - | |||||||
Total | $ | 896,000 | $ | 554,000 |
Accrued_Salaries_and_Payroll_T
Accrued Salaries and Payroll Taxes | 6 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Accrued Expense To Related Party [Abstract] | ' | ||||||||
Accrued Salaries and Payroll Taxes | ' | ||||||||
7. Accrued Salaries and Payroll Taxes | |||||||||
Accrued salaries and payroll taxes consisted of the following (rounded to nearest thousand): | |||||||||
31-Dec-13 | 30-Jun-13 | ||||||||
Accrued salaries – related parties | $ | 3,033,000 | $ | 3,244,000 | |||||
Accrued payroll taxes – related parties | 149,000 | 152,000 | |||||||
Withholding tax – related parties | 37,000 | 31,000 | |||||||
Withholding tax – employees | 19,000 | 4,000 | |||||||
Total | $ | 3,238,000 | $ | 3,431,000 | |||||
On December 29, 2010, the Company entered into employment agreements with its two executive officers, Leo Ehrlich, the Company’s Chief Executive Officer, and Krishna Menon, Chief Scientific Officer. Both agreements provide for a three year term with each executive receiving an annual base salary for $350,000 per year commencing January 1, 2011, with an annual increase of 10% for each year commencing January 2012. The Board, at its discretion, may increase the base salary based upon relevant circumstances. On January 1, 2014 the Board approved the extension of the employment agreements for a one year period with a 10% increase in salary from the calendar year 2013 annual salary of $423,500, to an annual salary of $465,850. |
Commitments_and_Contingencies
Commitments and Contingencies | 6 Months Ended | ||||
Dec. 31, 2013 | |||||
Commitments and Contingencies Disclosure [Abstract] | ' | ||||
Commitments and Contingencies | ' | ||||
8. Commitments and Contingencies | |||||
Legal | |||||
Formatech is a former vendor of ours which had had received 184,375 shares of Cellceutix Class A Common Stock (“Cellceutix Stock”) for services that were not completed. Formatech had gone bankrupt while still in possession of the Cellceutix Stock. In July 2012, the US Bankruptcy Court allowed the trustee of the Formatech estate to sell the Cellceutix Stock. We have been advised that the stock has been sold in 2013 and the funds released to the secured creditors of Formatech. Cellceutix presently is in the unsecured creditors class and does not expect to receive any proceeds. | |||||
Lease Commitments | |||||
Operating Leases | |||||
In September, 2013, Cellceutix Corporation signed a lease extension agreement with Cummings Properties for the company’s offices and laboratories at 100 Cummings Center, Suite 151-B Beverly, MA 01915. The lease is for a term of five years from October 1, 2013 to September 30, 2018 and requires monthly payments of $17,291. | |||||
Future minimum lease payments required under the non-cancelable operating lease are as follows: | |||||
Year ending June 30, | |||||
Remainder of 2014 | $ | 103,746 | |||
2015 | 207,492 | ||||
2016 | 207,492 | ||||
2017 | 207,492 | ||||
2018 | 207,492 | ||||
2019 | 51,873 | ||||
Total minimum payments | $ | 985,587 | |||
Rent expense under this operating lease agreement was $73,000 and $0 for the three months ended December 31, 2013 and 2012, respectively and $82,000 and $0 for the six months ended December 31, 2013 and 2012, respectively. Before September, 2013, the Company paid rent to KARD for share of office space and details were shown at Note 9 Related Party Transactions. | |||||
Contractual Commitments | |||||
Clinical Trial Agreements between the Company and Contract Research Organizations- ABSSSI Trial | |||||
In December 2013, the Company entered into Clinical Trial Agreements with a Contract Research Organization (“CRO”). Terms include the Company making an upfront study advance of approximately $460,000 to the CRO and seven additional similar monthly payments to the CRO while the study is actively recruiting and treating patients. The advance will be earned as subjects are randomized into the Study. The Company has other terms with the CRO which allow for a bonus payment of $125,000 if the CRO meets study milestones; a non-refundable administrative start-up cost of $12,500 per Study Site; payment to CRO for pass-through costs within thirty days of receipt of invoice and third-party documentation from CRO; and pass-through costs are subject to a 15% invoicing fee. | |||||
During the three months and six months ended December 31, 2013, the Company expensed $53,290 and recorded under research and development cost in the condensed consolidated statements of operations related to this CRO. | |||||
Clinical Trial Agreements between the Company and Contract Research Organizations- Phase 1 Trial | |||||
In December 2013, the Company entered into a Clinical Trial Agreement with a Contract Research Organization (“CRO”) to conduct a Phase 1 Pharmacokinetic and Bioequivalence study for the Company. The Company has agreed to pay the CRO approximately $185,000 for this study. As of December 31, 2013, the Company paid $73,476, which was recorded under Prepaid expenses in the accompanying condensed consolidated balance sheets. |
Related_Party_Transactions
Related Party Transactions | 6 Months Ended |
Dec. 31, 2013 | |
Related Party Transactions [Abstract] | ' |
Related Party Transactions | ' |
9. Related Party Transactions | |
Office Lease | |
Dr. Menon, the Company’s principal shareholder, President, and Director, also serves as the Chief Operating Officer and Director of Kard Scientific (“KARD”). On December 7, 2007, the Company began renting office space from KARD, on a month to month basis for $900 per month. This continued through August 2013 and since September 1, 2013, the Company no longer leases space from Kard. For the three and six months ended December 31, 2013 and 2012 and the period June 20, 2007 (date of inception) through December 31, 2013, the Company has included $0, $2,700, $1,800, $5,400 and $62,100 of rent expense paid to KARD in general and administrative expenses, respectively. At December 31, 2013 and June 30, 2013, payables of approximately $59,000 and $60,000 to KARD were included in accrued expenses, respectively. | |
In September 2013, Cellceutix Corporation signed a lease extension agreement with Cummings Properties for the company’s offices and laboratories at 100 Cummings Center, Suite 151-B Beverly, MA 01915. The lease is for a term of five years from October 1, 2013 to September 30, 2018 and requires monthly payments of $15,538. Cellceutix had taken over the space occupied by KARD. In addition, Innovative Medical Research Inc., (“Innovative Medical”) a company owned by Leo Ehrlich and Dr. Krishna Menon, officers of Cellecutix has co-signed the lease and will rent approximately 200 square feet of office space, the space previously used by Cellceutix and will pay Cellceutix $900 per month, the same amount Cellceutix previously paid KARD. Innovative Medical paid total rent of $3,600 to Cellceutix from September 1, 2013 to December 31, 2013 and the rent was offset with the accrued rent owed to KARD. | |
Clinical Studies | |
As of September 28, 2007 the Company engaged KARD to conduct specified pre-clinical studies. The Company did not have an exclusive arrangement with KARD. All work performed by KARD needed prior approval by the executive officers of the Company, and the Company retained all intellectual property resulting from the services by KARD. The Company has now developed its own research study capabilities and no longer uses KARD. For the three and six months ended December 31, 2013 and 2012 and the period June 20, 2007 (date of inception) through December 31, 2013, the Company incurred $0, $0, $0, $0, and $2,601,000 of research and development expenses conducted by KARD, respectively. | |
At December 31, 2013 and June 30, 2013, the Company has incurred a total of approximately $1,686,000 in accounts payable to KARD. |
Note_PayableRelated_Party
Note Payable-Related Party | 6 Months Ended |
Dec. 31, 2013 | |
Debt Disclosure [Abstract] | ' |
Note Payable - Related Party | ' |
10. Note Payable – Related Party | |
During the year ended June 30, 2010, Mr. Ehrlich loaned the Company a total of $972,907. A condition for this note was that the Ehrlich Promissory Note A and Ehrlich Promissory Note B be replaced with a new note, Ehrlich Promissory Note C. The Ehrlich Promissory Note C is an unsecured demand note that bears 9% simple interest per annum and is convertible into the Company’s common stock at $0.50 per share. The note requires that the interest rate on the amounts due on Ehrlich Promissory Notes A and B be changed retroactively, beginning October 1, 2009, to 9%. On April 1, 2011, the Company amended the Ehrlich Promissory Note C and agreed to retroactively convert accrued interest of $96,677 through December 31, 2010 into additional principal. During the year ended June 30, 2011, Mr. Ehrlich loaned the Company an additional $997,047 which brought the balance of the demand note to $2,002,264. | |
On May 8, 2012, the Company did not have the ability to repay the Ehrlich Promissory Note C loan and agreed to change the interest rate on the outstanding balance of principle and interest of $2,248,037, as of March 31, 2012, from 9% simple interest to 10% simple interest, and the Company issued 2,000,000 Equity Incentive Options exercisable at $0.51 per share equal to 110% of the closing bid price of $0.46 per share on May 7, 2012. Options are valid for ten (10) years from the date of issuance. | |
At December 31, 2013 and June 30, 2013, accrued interest on this note was approximately $365,000 and $294,000, respectively, and the Company repaid accrued interest totaling approximately $14,000 and $29,000 for the three and six months ended December 31, 2013. |
Stock_Options_and_Warrants
Stock Options and Warrants | 6 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | ||||||||||||||||
Stock Options and Warrants | ' | ||||||||||||||||
11. Stock Options and Warrants | |||||||||||||||||
Stock Options | |||||||||||||||||
The fair value of each option was estimated on the date of grant using the following Black-Scholes assumptions: | |||||||||||||||||
Six Months ended December 31, 2012 | |||||||||||||||||
Expected term (in years) | 10-May | ||||||||||||||||
Expected stock price volatility | 134.22% - 137.33 | % | |||||||||||||||
Risk-free interest rate | 1.53% - 1.75 | % | |||||||||||||||
Expected dividend yield | - | ||||||||||||||||
On April 5, 2009 the Board of Directors of the Registrant adopted the 2009 Stock Option Plan (“the Plan”). The Plan permits the grant of 2,000,000 shares of both Incentive Stock Options (“ISOs”), intended to qualify under section 422 of the Code, and Non-Qualified Stock Options. | |||||||||||||||||
Under the 2010 Equity Incentive Plan the total number of shares of Common Stock reserved and available for issuance under the Plan shall be 45,000,000 shares. Shares of Common Stock under the Plan (“Shares”) may consist, in whole or in part, of authorized and unissued shares or treasury shares. The term of each Stock Option shall be fixed by the Committee; provided, however, that an Incentive Stock Option may be granted only within the ten-year period commencing from the Effective Date and may only be exercised within ten years of the date of grant (or five years in the case of an Incentive Stock Option granted to an optionee who, at the time of grant, owns Common Stock possessing more than 10% of the total combined voting power of all classes of voting stock of the Company (“10%Shareholder”). | |||||||||||||||||
The following table summarizes all stock option activity under the plans: | |||||||||||||||||
Number of | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value | ||||||||||||||
Options | |||||||||||||||||
Outstanding at June 30, 2013 | 39,142,500 | $ | 0.14 | $ | 7.47 | $ | 64,170,000 | ||||||||||
Granted | - | - | - | ||||||||||||||
Exercised | - | - | - | ||||||||||||||
Forfeited/expired | - | - | - | ||||||||||||||
Outstanding at December 31, 2013 | 39,142,500 | $ | 0.14 | $ | 6.97 | $ | 76,303,275 | ||||||||||
Exercisable at December 31, 2013 | 39,137,500 | $ | 0.14 | $ | 6.97 | $ | 76,302,200 | ||||||||||
The Company recognized approximately $229,000, $138,000, $255,000 and $214,000 of stock based compensation costs related to stock and stock options awards for the three and six months ended December 31, 2013 and 2012; and approximately $6,591,000 for the period from inception to December 31, 2013, and there is approximately $8,000 of unamortized compensation cost expected to be recognized through June 30, 2014. | |||||||||||||||||
Stock Warrants | |||||||||||||||||
From July 19 to September 17, 2013, the Company issued 1,025,000 Class A common shares par value $.0001 to a warrant holder upon exercise of Common Stock Purchase Warrants exercisable at $1 per share. The Company received an aggregate of $1,025,000. The issuance was exempt from registration under Section 4(2) of the Securities Act. | |||||||||||||||||
On December 31, 2013, the Company issued 848,084 Class A common shares par value $.0001 to two warrant holders upon exercise of Common Stock Purchase Warrants exercisable at the range from $0.39 to $0.53 per share, with total of $400,000. The Company recorded $400,000 as a Subscription Receivable at December 31, 2013. The issuance was exempt from registration under Section 4(2) of the Securities Act. | |||||||||||||||||
Extension of the expiration date of an aggregate of 2,223,000 Series B, Series C, and Series D common share purchase warrants | |||||||||||||||||
On December 1, 2013, 2,223,000 Series B, Series C, and Series D common share purchase warrants issued by the Company were modified to extend their maturity date to December 31, 2015. As the Company is in an accumulated deficit position, the deemed dividend was charged against additional paid-in-capital for common shares, there being no retained earnings from which to declare a dividend. The net income (loss) attributable to common shareholders reflects both the net income (loss) and the deemed dividend. | |||||||||||||||||
The deemed dividend of $1,880,000 was computed as the incremental value of the modified warrants over the unmodified warrants on the modification date using a per share price of the range from $0.50 to $1.50 per share which were the contemporaneous private placement offering price, and the following other Black-Scholes assumptions: | |||||||||||||||||
Expected term (in years) | 2 | ||||||||||||||||
Expected stock price volatility | 55.22 | % | |||||||||||||||
Risk-free interest rate | 0.29 | % | |||||||||||||||
Expected dividend yield | 0 | ||||||||||||||||
The following table summarizes stock warrants as of December 31, 2013 and June 30, 2013: | |||||||||||||||||
Warrants | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value | ||||||||||||||
Outstanding at June 30, 2013 | 5,571,084 | $ | 0.92 | 1.43 | $ | 4,793,786 | |||||||||||
Extended | 2,223,000 | $ | 1 | 2 | |||||||||||||
Exercised | (1,873,084 | ) | $ | 1 | - | ||||||||||||
Forfeited/expired | (2,223,000 | ) | - | - | |||||||||||||
Outstanding at December 31, 2013 | 3,698,000 | $ | 1 | 1.56 | $ | 4,030,820 | |||||||||||
Exercisable at December 31, 2013 | 3,698,000 | $ | 1 | 1.56 | $ | 4,030,820 |
Equity_Transactions
Equity Transactions | 6 Months Ended |
Dec. 31, 2013 | |
Equity [Abstract] | ' |
Equity Transactions | ' |
12. Equity Transactions | |
Polymedix Trustee | |
On September 4, 2013, the Company purchased substantially all of the assets of Polymedix Inc, and Polymedix Pharmaceuticals, Inc. from the U.S. Bankruptcy Court. The purchase price included the issuance of 1,400,000 shares of the Company’s Class A common stock. | |
$20 million Class A Common Stock Purchase Agreement with Aspire Capital Fund, LLC | |
On October 25, 2013, we terminated a previous agreement with Aspire Capital Fund, LLC, an Illinois limited liability company (Aspire Capital), and entered into a new Class A Common Stock Purchase Agreement (the “Purchase Agreement”) with Aspire Capital, which provides that upon meeting the terms of the agreement, Aspire Capital is committed to purchase up to an aggregate of $20,000,000 of our shares of Class A Common Stock over the approximately 36-month term of the Purchase Agreement. In consideration for entering into the Purchase Agreement, the Company issued to Aspire Capital 210,523 shares of our Class A Common Stock as a commitment fee. The commitment fee of $373,000 will be amortized as the funding is received. No amortization was made during the three months ended December 31, 2013, because the Company did not sell any shares to Aspire regarding the new Purchase agreement of the $20 million during the six months ended December 31, 2013. The unamortized portion is carried on the balance sheet as deferred offering costs. | |
Concurrently with entering into the Purchase Agreement, the Company agreed to file one or more registration statements as permissible and necessary under the Securities Act of 1933, as amended, or the Securities Act, for the sale of shares of our Class A Common Stock that have been and may be issued to Aspire Capital under the Purchase Agreement. On November 4, 2013, the Company filed a Form S-3 registration statement and the registration statement was declared effective by the SEC on November 15, 2013. | |
Under the Purchase Agreement, on any trading day selected by Cellceutix which the closing sale price of our Class A Common Stock exceeds $0.25 per share, we may direct Aspire Capital to purchase up to 200,000 shares of our Class A Common Stock per trading day. The Purchase Price of such shares is equal to the lesser of a) the lowest sale price of our Class A Common Stock on the purchase date; or b) the arithmetic average of the three lowest closing sale prices for our Class A Common Stock during the twelve consecutive trading days ending on the trading day immediately preceding the purchase date. | |
In addition, on any date on which we submit a Purchase Notice to Aspire Capital for purchase of at least 100,000 Purchase Shares and the closing sale price of our stock is equal to or greater than $0.50 per share, we also have the right to direct Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the our Class A Common Stock traded on the OTC Bulletin Board on the next trading day, subject to the VWAP Purchase Share Volume Maximum and the VWAP Minimum Price Threshold, which is equal to the greater of (a) 90% of the closing price of our Class A Common Stock on the business day immediately preceding the VWAP Purchase Date or (b) such higher price as set forth by the Company in the VWAP Purchase Notice. The VWAP Purchase Price of such shares is the lower of (a) the Closing Sale Price on the VWAP Purchase Date; or 95% of the volume-weighted average price for our Class A Common Stock traded on the OTC Bulletin Board; and (b)on the VWAP Purchase Date, if the aggregate shares to be purchased on that date have not exceeded the VWAP Purchase Share Volume Maximum or during that portion of the VWAP Purchase Date until such time as the sooner to occur of (i) the time at which the aggregate shares traded on the OTC Bulletin Board exceed the VWAP Purchase Share Volume Maximum or (ii) the time at which the sale price of our Class A Common Stock falls below the VWAP Minimum Price Threshold. | |
The purchase price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the trading day(s) used to compute the purchase price. We may deliver multiple Purchase Notices and VWAP Purchase Notices to Aspire Capital from time to time during the term of the Purchase Agreement, so long as the most recent purchase has been completed. | |
Under the Purchase Agreement, we and Aspire Capital may not affect any sales of shares of our Class A Common Stock under the Purchase Agreement on any trading day that the closing sale price of our Class A Common Stock is less than $0.25 per share. | |
The Company is never under any obligation to sell shares to Aspire Capital Fund. Aspire Capital Fund has no rights to require the Company to sell shares. | |
During the six months ended December 31, 2013, the Company sold no shares to Aspire regarding the new Purchase agreement of the $20 million. As of December 31, 2013, the $20 million is available under the financing arrangement with Aspire on the sale of the Company’s common stock. From January 1, 2014 to January 31, 2014, the Company has generated additional proceeds of approximately $532,000 under the Common Stock Purchase Agreement with Aspire on the sale 300,000 shares of its common stock. | |
$10 million Class A Common Stock Purchase Agreement with Aspire Capital Fund, LLC | |
During the fiscal year ended June 30, 2013, the Company had completed sales to Aspire totaling 2,712,208 shares of common stock generating gross proceeds of approximately $4,383,000. During the six months ended December 31, 2013, the Company had completed sales to Aspire totaling 3,204,537 shares of common stock generating gross proceeds of approximately $5,618,000. As of October 24, 2013, Aspire Capital completed its commitment of purchase up to an aggregate of $10,000,000 of our shares of Class A Common Stock under the Common Stock Purchase Agreement dated December 6, 2012. | |
Exercise of Common Stock Purchase Warrants | |
From July 19 to September 17, 2013, the Company issued 1,025,000 Class A common shares par value $.0001 to a warrant holder upon exercise of Common Stock Purchase Warrants exercisable at $1 per share. The Company received an aggregate of $1,025,000. The issuance was exempt from registration under Section 4(2) of the Securities Act. | |
On December 31, 2013, the Company issued 848,084 Class A common shares par value $.0001 to two warrant holders upon exercise of Common Stock Purchase Warrants exercisable at the range from $0.39 to $0.53 per share, with total of $400,000. The Company recorded $400,000 under Subscription Receivable for the check was cleared until January 3, 2014. The issuance was exempt from registration under Section 4(2) of the Securities Act. | |
Issuance of Common Stock to Consultants and Employees | |
On December 17, 2013, the Company issued 5,000 shares of restricted Class A common shares par value $.0001 to one consultant valued at approximately $9,000. | |
On December 31, 2013, the Company issued 50,000 shares of restricted Class A common shares par value $.0001 to two consultants valued at approximately $105,000. | |
On December 31, 2013, the Company issued 60,000 shares of restricted Class A common shares par value $.0001 to six employees as a year end bonus valued at approximately $96,000. | |
On October 17, 2013, the Board of Directors approved the stock grant of 35,000 shares of restricted common stock to be issued and vested on January 6, 2014 to a consultant valued at approximately $70,000. This $70,000 of stock based compensation expense was accrued at December 31, 2013. |
Subsequent_Events
Subsequent Events | 6 Months Ended |
Dec. 31, 2013 | |
Subsequent Events [Abstract] | ' |
Subsequent Events | ' |
13. Subsequent Events | |
Equity Transactions | |
Extension of the Employment Agreement | |
On January 1, 2014, the Board of Directors of the Company resolved and approved the extension of the Employment Agreement by and between the Company and Leo Ehrlich, and by and between the Company and Krishna Menon, each for a one year period with a 10% increase in salary from the current annual salary of $423,500 to an annual salary of $465,850. | |
Exercise of Warrants | |
On January 3, 2014, the Board of Directors of the Company authorized the Exercise of 200,000 Warrants into 200,000 shares of Common Stock by Huang Min Chung, followed by the resolution of the extension of the expiration date of an aggregate of 2,223,000 Series B, Series C, and Series D common share purchase warrants of the Company to December 31, 2015 made by the Board of Directors on December 1, 2013. It was resolved that the Board of Directors approved the issuance 200,000 fully paid Common shares par value $0.0001 per share, of the capital stock of Cellceutix Corporation to Huang Min Chung which shares have been registered in the S-3 registration statement rendered effective February 14, 2013 by the SEC. | |
Issuance of Common Stock to Consultant | |
On January 23, 2014, the Company granted a total of 100,000 shares and options to two consultants. This issuance to each consultant is comprised of 25,000 shares of restricted common stock and 25,000 stock options exercisable at $1.79 a share. The shares will be vested on March 31, 2014 and the option life is three years. | |
Issuance of Common Stock to Aspire | |
From January 1, 2014 to January 31, 2014, the Company has generated additional proceeds of approximately $532,000 under the Common Stock Purchase Agreement with Aspire on the sale 300,000 shares of its common stock. |
Significant_Accounting_Policie1
Significant Accounting Policies and Recent Accounting Pronouncements (Policies) | 6 Months Ended | ||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||||||
Cash and Cash Equivalents | ' | ||||||||||||||||||||
Cash and Cash Equivalents | |||||||||||||||||||||
Cash and cash equivalents consist of cash and short-term highly liquid investments purchased with original maturities of three months or less. There were no cash equivalents at December 31, 2013 and June 30, 2013. | |||||||||||||||||||||
Intangible Assets - Patents | ' | ||||||||||||||||||||
Intangible Assets – Patents | |||||||||||||||||||||
Costs incurred to file patent applications and acquired intangibles are capitalized when the Company believes that there is a high likelihood that the patent will issue and there will be future economic benefit associated with the patent. These costs will be amortized on a straight-line basis over a 12 - 17 years life from the date of patent filing. All costs associated with abandoned patent applications are expensed. In addition, the Company will review the carrying value of patents for indicators of impairment on a periodic basis and if it determines that the carrying value is impaired, it values the patent at fair value. Costs incurred to file patent applications and acquire intangibles are expensed when the patents have failed to develop products which have gained market acceptance. For the three months ended December 31, 2013 and 2012, the Company has charged to operations approximately $0 and $20,000, respectively for these patent application costs. For the six months ended December 31, 2013 and 2012 and from inception to December 31, 2013, the Company has charged to operations $0, $29,000, and $197,000, respectively for these patent application costs | |||||||||||||||||||||
In accordance with the provisions of the applicable authoritative guidance, the Company’s long-lived assets and amortizable intangible assets are tested for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. The Company assesses the recoverability of such assets by determining whether their carrying value can be recovered through undiscounted future operating cash flows, including its estimates of revenue driven by assumed market segment share and estimated costs. If impairment is indicated, the Company measures the amount of such impairment by comparing the fair value to the carrying value. During the three and six months ended December 31, 2013 and 2012, no impairment was recorded. | |||||||||||||||||||||
Financial Instruments | ' | ||||||||||||||||||||
Financial Instruments | |||||||||||||||||||||
The Company’s financial instruments include cash, accounts payable and accrued liabilities. The carrying amounts of these financial instruments approximate their fair value, due to the short-term nature of these items. | |||||||||||||||||||||
Use of Estimates | ' | ||||||||||||||||||||
Use of Estimates | |||||||||||||||||||||
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |||||||||||||||||||||
Significant Estimates | ' | ||||||||||||||||||||
Significant Estimates | |||||||||||||||||||||
These accompanying consolidated financial statements include some amounts that are based on management’s best estimates and judgments. The most significant estimates relate to valuation of stock grants and stock options, valuation of purchased intangibles and the valuation allowance on deferred tax assets. It is reasonably possible that these above-mentioned estimates and others may be adjusted as more current information becomes available, and any adjustment could be significant in future reporting periods. | |||||||||||||||||||||
Certain Risks and Uncertainties | ' | ||||||||||||||||||||
Certain Risks and Uncertainties | |||||||||||||||||||||
Product Development | |||||||||||||||||||||
We devote significant resources to research and development programs in an effort to discover and develop potential future product candidates. The product candidates in our pipeline are at various stages of preclinical and clinical development. The path to regulatory approval includes three phases of clinical trials in which we collect data to support an application to regulatory authorities to allow us to market a product for treatment of a specified disease. There are many difficulties and uncertainties inherent in research and development of new products, resulting in a high rate of failure. To bring a drug from the discovery phase to regulatory approval, and ultimately to market, takes many years and significant cost. Failure can occur at any point in the process, including after the product is approved, based on post-market factors. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain necessary regulatory approvals, limited scope of approved uses, reimbursement challenges, difficulty or excessive costs of manufacture, alternative therapies or infringement of the patents or intellectual property rights of others. Uncertainties in the FDA approval process and the approval processes in other countries can result in delays in product launches and lost market opportunities. Consequently, it is very difficult to predict which products will ultimately be submitted for approval, which have the highest likelihood of obtaining approval and which will be commercially viable and generate profits. Successful results in preclinical or clinical studies may not be an accurate predictor of the ultimate safety or effectiveness of a drug or product candidate. | |||||||||||||||||||||
Expenditures for research, development, and engineering of products are expensed as incurred. In November 2010, the Company was awarded three separate U.S. government grants under the Qualifying Therapeutic Discovery Project (QTDP) program. For the period from inception to December 31, 2013, the Company has reflected $733,438 of grants as a one time reduction of research and development expenses. For the three months ended December 31, 2013 and 2012, and the period from inception to December 31, 2013, the Company incurred approximately $1,014,000 and $282,000of research and development costs, net of grants respectively. For the six months ended December 31, 2013 and 2012, and the period from inception to December 31, 2013, the Company incurred approximately $1,586,000, $466,000, and $7,459,000 of research and development costs, net of grants respectively. | |||||||||||||||||||||
Concentrations of Credit Risk | ' | ||||||||||||||||||||
Concentrations of Credit Risk | |||||||||||||||||||||
All cash is maintained with a major financial institution in the United States. Deposits with this bank may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. | |||||||||||||||||||||
Income Taxes | ' | ||||||||||||||||||||
Income Taxes | |||||||||||||||||||||
Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. | |||||||||||||||||||||
The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes. The deferred tax assets were primarily comprised of federal and state tax net operating loss, or NOL, carryforwards. Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these tax assets, a full valuation allowance has been established to offset the deferred tax assets. Additionally, the future utilization of the NOL carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that could occur in the future. If necessary, the deferred tax assets will be reduced by any carryforwards that expire prior to utilization as a result of such limitations, with a corresponding reduction of the valuation allowance. | |||||||||||||||||||||
The Company follows the provisions of FASB ASC 740-10 "Uncertainty in Income Taxes" (ASC 740-10). The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. | |||||||||||||||||||||
The Company has identified its U.S. Federal income tax return and its State return in Massachusetts as its major tax jurisdictions. The fiscal 2011 and forward years are still open for examination. | |||||||||||||||||||||
Basic Earnings (Loss) per Share | ' | ||||||||||||||||||||
Basic Earnings (Loss) per Share | |||||||||||||||||||||
Basic and diluted earnings per share are computed based on the weighted-average common shares and common share equivalents outstanding during the period. Common share equivalents consist of stock options, warrants and convertible notes payable. Common share equivalents of approximately 47.6 million and 50 million were excluded from the computation of diluted earnings per share as of December 31, 2013 and 2012, respectively, have been excluded from the per share computations for the three and six months ended December 31, 2013 and 2012, because their effect is anti-dilutive. | |||||||||||||||||||||
Accounting for Stock Based Compensation | ' | ||||||||||||||||||||
Accounting for Stock Based Compensation | |||||||||||||||||||||
The stock-based compensation expense incurred by Cellceutix for employees and directors in connection with its stock option plan is based on the employee model of ASC 718, and the fair market value of the options is measured at the grant date. Under ASC 718 employee is defined as “An individual over whom the grantor of a share-based compensation award exercises or has the right to exercise sufficient control to establish an employer-employee relationship based on common law as illustrated in case law and currently under U.S.“tax regulations”. Our consultants do not meet the employer-employee relationship as defined by the IRS and therefore are accounted for under ASC 505-50. | |||||||||||||||||||||
ASC 505-50-30-11 (previously EITF 96-18) further provides that an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: | |||||||||||||||||||||
i. | The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and | ||||||||||||||||||||
ii. | The date at which the counterparty’s performance is complete. | ||||||||||||||||||||
We have elected to use the Black-Scholes-Merton pricing model to determine the fair value of stock options on the dates of grant. Restricted stock units are measured based on the fair market values of the underlying stock on the dates of grant. We recognize stock-based compensation using the straight-line method. | |||||||||||||||||||||
The components of stock based compensation related to stock options recognized in the Company’s Statement of Operations for the three and six months ended December 31, 2013 and 2012 and since inception are as follows(rounded to nearest thousand): | |||||||||||||||||||||
Three Months Ended December 31, 2013 | Three Months Ended December 31, 2012 | Six Months Ended December 31, 2012 | For the cumulative period from June 20, 2007 (Date of Inception) through December 31, 2013 | ||||||||||||||||||
Six Months Ended December 31, 2013 | |||||||||||||||||||||
Employee’s stock compensation | $ | 105,000 | $ | - | $ | 105,000 | $ | - | $ | 105,000 | |||||||||||
Officers’ stock compensation | - | - | - | - | 4,850,000 | ||||||||||||||||
Consulting | 124,000 | 138,000 | 150,000 | 214,000 | 1,617,000 | ||||||||||||||||
Patent expense | - | - | - | - | 19,000 | ||||||||||||||||
Total | $ | 229,000 | $ | 138,000 | $ | 255,000 | $ | 214,000 | $ | 6,591,000 | |||||||||||
Recent Accounting Pronouncements | ' | ||||||||||||||||||||
Recent Accounting Pronouncements | |||||||||||||||||||||
The Company has reviewed all recent accounting pronouncements issued by FASB (including EITF), the AICPA and the SEC and did not or are not believed by management to have a material impact on the Company’s present or future financial statements. |
Significant_Accounting_Policie2
Significant Accounting Policies and Recent Accounting Pronouncements (Tables) | 6 Months Ended | ||||||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||||||
Schedule of components of stock based compensation related to stock options recognized in the company's statement of operations | ' | ||||||||||||||||||||
Three Months Ended December 31, 2013 | Three Months Ended December 31, 2012 | Six Months Ended December 31, 2012 | For the cumulative period from June 20, 2007 (Date of Inception) through December 31, 2013 | ||||||||||||||||||
Six Months Ended December 31, 2013 | |||||||||||||||||||||
Employee’s stock compensation | $ | 105,000 | $ | - | $ | 105,000 | $ | - | $ | 105,000 | |||||||||||
Officers’ stock compensation | - | - | - | - | 4,850,000 | ||||||||||||||||
Consulting | 124,000 | 138,000 | 150,000 | 214,000 | 1,617,000 | ||||||||||||||||
Patent expense | - | - | - | - | 19,000 | ||||||||||||||||
Total | $ | 229,000 | $ | 138,000 | $ | 255,000 | $ | 214,000 | $ | 6,591,000 |
Polymedix_Inc_Asset_Acquisitio1
Polymedix Inc. Asset Acquisition Patent Rights and Equipment (Tables) | 6 Months Ended | ||||
Dec. 31, 2013 | |||||
Business Combinations [Abstract] | ' | ||||
Schedule of purchase price allocation for the assets acquired | ' | ||||
Intangible assets – patents rights – Brilacidin, Delparantag and other related compounds | $ | 4,706,000 | |||
Tangible assets - Laboratory equipment and computer systems | $ | 96,000 |
Patents_net_Tables
Patents, net (Tables) | 6 Months Ended | ||||||||||||
Dec. 31, 2013 | |||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | ||||||||||||
Schedule of patents | ' | ||||||||||||
Useful life | 31-Dec-13 | 30-Jun-13 | |||||||||||
Purchased Patent Rights– Brilacidin, and related compounds (note 4) | 14 | $ | 4,082,000 | $ | - | ||||||||
Purchased Patent Rights–Delparantag and related compounds (note 4) | 12 | 480,000 | - | ||||||||||
Purchased Patent Rights–Anti-microbial- surfactants and related compounds (note 4) | 12 | 144,000 | - | ||||||||||
Patents – Kevetrin and related compounds | 17 | 45,000 | 11,000 | ||||||||||
$ | 4,751,000 | $ | 11,000 | ||||||||||
Accumulated amortization | 102,000 | 1,000 | |||||||||||
$ | 4,649,000 | $ | 10,000 |
Accrued_Expenses_Tables
Accrued Expenses (Tables) | 6 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Accrued Expenses [Abstract] | ' | ||||||||
Schedule of accrued expenses | ' | ||||||||
31-Dec-13 | 30-Jun-13 | ||||||||
Accrued research and development consulting fees | $ | 459,000 | $ | 200,000 | |||||
Accrued rent – related parties | 59,000 | 60,000 | |||||||
Accrued interest – related parties | 365,000 | 294,000 | |||||||
Others | 13,000 | - | |||||||
Total | $ | 896,000 | $ | 554,000 |
Accrued_Salaries_and_Payroll_T1
Accrued Salaries and Payroll Taxes (Tables) | 6 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Accrued Expense To Related Party [Abstract] | ' | ||||||||
Schedule of accrued salaries and payroll taxes | ' | ||||||||
31-Dec-13 | 30-Jun-13 | ||||||||
Accrued salaries – related parties | $ | 3,033,000 | $ | 3,244,000 | |||||
Accrued payroll taxes – related parties | 149,000 | 152,000 | |||||||
Withholding tax – related parties | 37,000 | 31,000 | |||||||
Withholding tax – employees | 19,000 | 4,000 | |||||||
Total | $ | 3,238,000 | $ | 3,431,000 |
Commitments_and_Contingencies_
Commitments and Contingencies (Tables) | 6 Months Ended | ||||
Dec. 31, 2013 | |||||
Commitments and Contingencies Disclosure [Abstract] | ' | ||||
Future minimum lease payments required under the non-cancelable operating lease | ' | ||||
Year ending June 30, | |||||
Remainder of 2014 | $ | 103,746 | |||
2015 | 207,492 | ||||
2016 | 207,492 | ||||
2017 | 207,492 | ||||
2018 | 207,492 | ||||
2019 | 51,873 | ||||
Total minimum payments | $ | 985,587 |
Stock_Options_and_Warrants_Tab
Stock Options and Warrants (Tables) | 6 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Valuation assumptions for stock options/warrants and SARs | ' | ||||||||||||||||
Six Months ended December 31, 2012 | |||||||||||||||||
Expected term (in years) | 10-May | ||||||||||||||||
Expected stock price volatility | 134.22% - 137.33 | % | |||||||||||||||
Risk-free interest rate | 1.53% - 1.75 | % | |||||||||||||||
Expected dividend yield | - | ||||||||||||||||
Schedule of stock option activity | ' | ||||||||||||||||
Number of Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value | ||||||||||||||
Outstanding at June 30, 2013 | 39,142,500 | $ | 0.14 | $ | 7.47 | $ | 64,170,000 | ||||||||||
Granted | - | - | - | ||||||||||||||
Exercised | - | - | - | ||||||||||||||
Forfeited/expired | - | - | - | ||||||||||||||
Outstanding at December 31, 2013 | 39,142,500 | $ | 0.14 | $ | 6.97 | $ | 76,303,275 | ||||||||||
Exercisable at December 31, 2013 | 39,137,500 | $ | 0.14 | $ | 6.97 | $ | 76,302,200 | ||||||||||
Warrants | ' | ||||||||||||||||
Valuation assumptions for stock options/warrants and SARs | ' | ||||||||||||||||
Expected term (in years) | 2 | ||||||||||||||||
Expected stock price volatility | 55.22 | % | |||||||||||||||
Risk-free interest rate | 0.29 | % | |||||||||||||||
Expected dividend yield | 0 | ||||||||||||||||
Schedule of stock option activity | ' | ||||||||||||||||
Warrants | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value | ||||||||||||||
Outstanding at June 30, 2013 | 5,571,084 | $ | 0.92 | 1.43 | $ | 4,793,786 | |||||||||||
Extended | 2,223,000 | $ | 1 | 2 | |||||||||||||
Exercised | (1,873,084 | ) | $ | 1 | - | ||||||||||||
Forfeited/expired | (2,223,000 | ) | - | - | |||||||||||||
Outstanding at December 31, 2013 | 3,698,000 | $ | 1 | 1.56 | $ | 4,030,820 | |||||||||||
Exercisable at December 31, 2013 | 3,698,000 | $ | 1 | 1.56 | $ | 4,030,820 |
Going_Concern_Details_Textual
Going Concern (Details Textual) (USD $) | Dec. 31, 2013 | Jun. 30, 2013 |
Agreement [Table] | ' | ' |
Deficit accumulated during the development stage | ($22,346,718) | ($19,773,202) |
Working capital surplus (deficit) | 3,800,000 | ' |
Aspire Capital Fund Llc [Member] | Financing Agreement [Member] | ' | ' |
Agreement [Table] | ' | ' |
Working capital fund obtained from financing agreement | $20,000,000 | ' |
Significant_Accounting_Policie3
Significant Accounting Policies and Recent Accounting Pronouncements (Details) (USD $) | 3 Months Ended | 6 Months Ended | 78 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Total | $105,250 | ' | $105,250 | ' | $105,250 |
Employee Stock Option [Member] | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Employee's stock compensation | 105,000 | ' | 105,000 | ' | 105,000 |
Officers' stock compensation | ' | ' | ' | ' | 4,850,000 |
Consulting | 124,000 | 138,000 | 150,000 | 214,000 | 1,617,000 |
Patent expense | ' | ' | ' | ' | 19,000 |
Total | $229,000 | $138,000 | $255,000 | $214,000 | $6,591,000 |
Significant_Accounting_Policie4
Significant Accounting Policies and Recent Accounting Pronouncements (Detail Textual) (USD $) | 3 Months Ended | 6 Months Ended | 78 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Working Capital Surplus Deficit [Line Items] | ' | ' | ' | ' | ' |
Amount charged to operations | $0 | $20,000 | $0 | $29,000 | $197,000 |
Common stock share grants for research and development | ' | ' | ' | ' | 733,438 |
Research and development, net of grants | $1,013,570 | $281,516 | $1,585,776 | $466,469 | $7,459,231 |
Antidilutive common share equivalents excluded from the computation of diluted earnings per share | ' | ' | 49,761,768 | 52,014,317 | ' |
Minimum | ' | ' | ' | ' | ' |
Working Capital Surplus Deficit [Line Items] | ' | ' | ' | ' | ' |
Amortization period | ' | ' | '12 years | ' | ' |
Maximum | ' | ' | ' | ' | ' |
Working Capital Surplus Deficit [Line Items] | ' | ' | ' | ' | ' |
Amortization period | ' | ' | '17 years | ' | ' |
Polymedix_Inc_Asset_Acquisitio2
Polymedix Inc. Asset Acquisition - Patent Rights and Equipment (Details) (Polymedix Inc And Polymedix Pharmaceuticals Inc [Member], USD $) | Sep. 04, 2013 |
Polymedix Inc And Polymedix Pharmaceuticals Inc [Member] | ' |
Business Acquisition [Line Items] | ' |
Intangible assets - patents rights - Brilacidin, Delparantag and other related compounds | $4,706,000 |
Tangible assets - Laboratory equipment and computer systems | $96,000 |
Polymedix_Inc_Asset_Acquisitio3
Polymedix Inc. Asset Acquisition - Patent Rights and Equipment (Details Textual) (USD $) | 1 Months Ended | 0 Months Ended | |
Sep. 30, 2013 | Sep. 04, 2013 | Sep. 04, 2013 | |
Polymedix Inc And Polymedix Pharmaceuticals Inc [Member] | Polymedix Inc And Polymedix Pharmaceuticals Inc [Member] | ||
Common Class A [Member] | |||
Business Acquisition [Line Items] | ' | ' | ' |
Payment in cash in asset acquisition | ' | $21 | ' |
Number of shares issued under asset acquisition | ' | ' | 14 |
Aggregate purchase price | ' | 48 | ' |
Issue price per share for stock issued under asset acquisition | ' | $1.93 | ' |
Stock issued to acquire the purchased assets | ' | 27 | ' |
Per share price of repurchase the registrable securities | ' | $1 | ' |
Number Of Potential Shares Needed To Repurchase Common Stock Under Put Option | ' | 1,400,000 | ' |
Redeemable common stock liability | ' | 1,400,000 | ' |
Value of tangible assets acquired expensed | $96,000 | ' | ' |
Patents_net_Details
Patents, net (Details) (USD $) | 6 Months Ended | |
Dec. 31, 2013 | Jun. 30, 2013 | |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Purchased Patent Rights | $4,751,000 | $11,000 |
Accumulated amortization | 102,000 | 1,000 |
Patent costs - net | 4,649,000 | 10,000 |
Patents [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Useful life | '14 years | ' |
Purchased Patent Rights | 4,082,000 | ' |
Patents Two [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Useful life | '12 years | ' |
Purchased Patent Rights | 480,200 | ' |
Patents Three [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Useful life | '12 years | ' |
Purchased Patent Rights | 144,000 | ' |
Patents Four [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Useful life | '17 years | ' |
Purchased Patent Rights | $45,000 | $11,000 |
Patents_net_Details_Textual
Patents, net (Details Textual) (USD $) | 3 Months Ended | 6 Months Ended | 78 Months Ended | 6 Months Ended | 3 Months Ended | ||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | |
Minimum | Maximum | Year 2014-28 [Member] | Year 2029 [Member] | ||||||
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Estimated remaining useful lives of the assets | ' | ' | ' | ' | ' | '12 years | '17 years | ' | ' |
Amortization expense | $80,000 | $0 | $101,844 | $501 | $102,460 | ' | ' | ' | ' |
Amortization period | ' | ' | ' | ' | ' | '11 years 9 months | '16 years 9 months | ' | ' |
Estimated annual amortization expense | ' | ' | ' | ' | ' | ' | ' | $316,000 | $3,000 |
Accrued_Expenses_Details
Accrued Expenses (Details) (USD $) | Dec. 31, 2013 | Jun. 30, 2013 |
Accrued Expenses [Abstract] | ' | ' |
Accrued research and development consulting fee | $459,000 | $200,000 |
Accrued rent - related parties | 59,000 | 60,000 |
Accrued interest - related parties | 365,000 | 294,000 |
Others | 13,000 | ' |
Total | $895,809 | $553,797 |
Accrued_Salaries_and_Payroll_T2
Accrued Salaries and Payroll Taxes (Details) (USD $) | Dec. 31, 2013 | Jun. 30, 2013 |
Accrued Expense To Related Party [Abstract] | ' | ' |
Accrued salaries - related parties | $3,033,000 | $3,244,000 |
Accrued payroll taxes - related parties | 149,000 | 152,000 |
Withholding tax-related parties | 37,000 | 31,000 |
Withholding tax-employee | 19,000 | 4,000 |
Total | $3,238,000 | $3,431,000 |
Accrued_Salaries_and_Payroll_T3
Accrued Salaries and Payroll Taxes (Details Textual) (USD $) | 1 Months Ended | 6 Months Ended |
Dec. 29, 2010 | Dec. 31, 2013 | |
Officer | ||
Related Party Transaction [Line Items] | ' | ' |
Number of executive officers | 2 | ' |
Percentage of annual increase in salary | 10.00% | 10.00% |
Term of agreement | '3 years | ' |
Executive's annual salary current | ' | $423,500 |
Subsequent Event [Member] | ' | ' |
Related Party Transaction [Line Items] | ' | ' |
Executive's annual salary increased | ' | 465,850 |
Chief Scientific Officer [Member] | ' | ' |
Related Party Transaction [Line Items] | ' | ' |
Executive's annual base salary | 350,000 | ' |
Chief Executive Officer [Member] | ' | ' |
Related Party Transaction [Line Items] | ' | ' |
Executive's annual base salary | 350,000 | ' |
Commitments_and_Contingencies_1
Commitments and Contingencies (Details) (USD $) | Dec. 31, 2013 |
Commitments and Contingencies Disclosure [Abstract] | ' |
Year ending June 30, Remainder of 2014 | $103,746 |
2015 | 207,492 |
2016 | 207,492 |
2017 | 207,492 |
2018 | 207,492 |
2019 | 51,873 |
Total minimum payments | $985,587 |
Commitments_and_Contingencies_2
Commitments and Contingencies (Details Textual) (USD $) | 3 Months Ended | 6 Months Ended | |||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2013 | |
Agreement [Table] | ' | ' | ' | ' | ' |
Monthly payments of operating leases | $17,291 | ' | $17,291 | ' | ' |
Operating leases, rental expense | 73,000 | 0 | 82,000 | 0 | ' |
Prepaid expenses | 165,154 | ' | 165,154 | ' | 4,796 |
Contract Research Organization (CRO) - ABSSSI Trial [Member] | ' | ' | ' | ' | ' |
Agreement [Table] | ' | ' | ' | ' | ' |
Study advance | ' | ' | 460,000 | ' | ' |
Bonus payment | ' | ' | 125,000 | ' | ' |
Non-refundable administrative start-up cost | ' | ' | 12,500 | ' | ' |
Invoicing fee percentage | ' | ' | 15.00% | ' | ' |
Research and development cost | 53,290 | ' | 53,290 | ' | ' |
Contract Research Organization (CRO) - Phase 1 Trial [Member] | ' | ' | ' | ' | ' |
Agreement [Table] | ' | ' | ' | ' | ' |
Study advance | ' | ' | 185,000 | ' | ' |
Prepaid expenses | $73,476 | ' | $73,476 | ' | ' |
Formatech [Member] | Common Class A [Member] | ' | ' | ' | ' | ' |
Agreement [Table] | ' | ' | ' | ' | ' |
Shares issued for services (in shares) | ' | ' | 184,375 | ' | ' |
Related_Party_Transactions_Det
Related Party Transactions (Details Textual) (USD $) | 3 Months Ended | 6 Months Ended | 78 Months Ended | ||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Jun. 30, 2013 | Dec. 07, 2007 | |
Related Party Transaction [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Rent payables included in general and administrative expenses | $0 | $2,700 | $1,800 | $5,400 | $62,100 | ' | ' |
Research and development expenses | 1,013,570 | 281,516 | 1,585,776 | 466,469 | 8,192,669 | ' | ' |
Accounts payable, related party payables | 1,707,576 | ' | 1,707,576 | ' | 1,707,576 | 1,703,916 | ' |
Kard Scientific [Member] | ' | ' | ' | ' | ' | ' | ' |
Related Party Transaction [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Office space rent (per month) | 900 | ' | 900 | ' | 900 | ' | 900 |
Rent payables included in accrued expenses | 59,000 | ' | 59,000 | ' | 59,000 | 60,000 | ' |
Research and development expenses | 0 | 0 | 0 | 0 | 2,601,000 | ' | ' |
Accounts payable, related party payables | ' | ' | ' | ' | ' | 1,686,000 | ' |
Leo Ehrlich And Dr Krishna Menon Officers [Member] | ' | ' | ' | ' | ' | ' | ' |
Related Party Transaction [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Area of office space | 200 | ' | 200 | ' | 200 | ' | ' |
Lease Extension Agreement [Member] | ' | ' | ' | ' | ' | ' | ' |
Related Party Transaction [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Office space rent (per month) | $15,538 | ' | $15,538 | ' | $15,538 | ' | ' |
Lease term | ' | ' | '5 years | ' | ' | ' | ' |
Note_Payable_Related_Party_Det
Note Payable - Related Party (Details Textual) (USD $) | Dec. 31, 2013 | Jun. 30, 2013 | Mar. 31, 2012 | Jun. 30, 2011 | Jun. 30, 2010 | Apr. 01, 2011 | Oct. 01, 2009 | Oct. 01, 2009 | 8-May-12 | Dec. 31, 2013 | Jun. 30, 2013 | 7-May-12 |
Convertible Notes Payable [Member] | Convertible Notes Payable [Member] | Convertible Notes Payable [Member] | Convertible Notes Payable [Member] | Convertible Notes Payable [Member] | Convertible Notes Payable [Member] | Promissory Note Payable C [Member] | Promissory Note Payable C [Member] | Promissory Note Payable C [Member] | Promissory Note Payable C [Member] | |||
Officer [Member] | Officer [Member] | Officer [Member] | Officer [Member] | Officer [Member] | Officer [Member] | Officer [Member] | Officer [Member] | Officer [Member] | ||||
Promissory Note Payable C [Member] | Promissory Note Payable C [Member] | Promissory Note Payable C [Member] | Promissory Note Payable [Member] | Promissory Note Payable B [Member] | ||||||||
Debt Instrument [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unsecured Ehrlich Promissory Note - total amount | ' | ' | ' | $997,047 | $972,907 | ' | ' | ' | ' | ' | ' | ' |
Simple interest bearing unsecured Ehrlich Promissory Note | ' | ' | 9.00% | ' | 9.00% | ' | ' | ' | ' | ' | ' | ' |
Common stock per share | ' | ' | ' | ' | $0.50 | ' | ' | ' | ' | ' | ' | ' |
Percentage of interest rate change | ' | ' | 10.00% | ' | ' | ' | 9.00% | 9.00% | ' | ' | ' | ' |
Debt instrument accrued interest converted into additional principal | ' | ' | ' | ' | ' | 96,677 | ' | ' | ' | ' | ' | ' |
Note payable to officer | 2,022,264 | 2,022,264 | 2,248,037 | 2,002,264 | ' | ' | ' | ' | ' | ' | ' | ' |
Number of shares converted | ' | ' | ' | ' | ' | ' | ' | ' | 2,000,000 | ' | ' | ' |
Bid price of shares converted | ' | ' | ' | ' | ' | ' | ' | ' | $0.51 | ' | ' | $0.46 |
Percentage of bid price | ' | ' | ' | ' | ' | ' | ' | ' | 110.00% | ' | ' | ' |
Term of shares | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' | ' | ' |
Interest accrued | ' | ' | ' | ' | ' | ' | ' | ' | ' | 365,000 | 294,000 | ' |
Repayment of accrued interest | ' | ' | ' | ' | ' | ' | ' | ' | ' | $29,000 | ' | ' |
Stock_Options_and_Warrants_Det
Stock Options and Warrants (Details) | 6 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | |
Warrants | Minimum | Maximum | |
Employee Stock Option [Member] | Employee Stock Option [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Expected term (in years) | '2 years | '5 years | '10 years |
Expected stock price volatility | 55.22% | 134.22% | 137.33% |
Risk-free interest rate | 0.29% | 1.53% | 1.72% |
Expected dividend yield | 0.00% | ' | ' |
Stock_Options_and_Warrants_Det1
Stock Options and Warrants (Details 1) (USD $) | 6 Months Ended |
Dec. 31, 2013 | |
Share-based Compensation Arrangement by Share-based Payment Award, Outstanding | ' |
Outstanding at June 30, 2013 | 39,142,500 |
Granted/Extended | ' |
Forfeited/expired | ' |
Outstanding at December 31, 2013 | 39,142,500 |
Exercisable at December 31, 2013 | 39,137,500 |
Share-based Compensation Arrangement by Share-based Payment Award, Outstanding, Weighted Average Exercise Price | ' |
Outstanding at June 30, 2013 | $0.14 |
Granted/Extended | ' |
Exercised | ' |
Forfeited/expired | ' |
Outstanding at December 31, 2013 | $0.14 |
Exercisable at December 31, 2013 | $0.14 |
Share-Based Compensation Arrangement By Share-Based Payment Award, Outstanding, Weighted Average Remaining Contractual Term | ' |
Weighted average remaining contractual life (Years), Outstanding | '7 years 5 months 19 days |
Weighted average remaining contractual life (Years), Outstanding | '6 years 11 months 19 days |
Weighted average remaining contractual life (Years), Exercisable | '6 years 11 months 19 days |
Aggregate intrinsic value, Outstanding | $64,170,000 |
Aggregate intrinsic value, Outstanding | 7,630,327,500 |
Aggregate intrinsic value, Exercisable | 7,630,327,500 |
Warrants | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Outstanding | ' |
Outstanding at June 30, 2013 | 5,571,084 |
Granted/Extended | 2,223,000 |
Exercised | -1,873,084 |
Forfeited/expired | -2,223,000 |
Outstanding at December 31, 2013 | 3,698,000 |
Exercisable at December 31, 2013 | 3,698,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Outstanding, Weighted Average Exercise Price | ' |
Outstanding at June 30, 2013 | $0.92 |
Granted/Extended | $1 |
Exercised | $1 |
Outstanding at December 31, 2013 | $1 |
Exercisable at December 31, 2013 | $1 |
Share-Based Compensation Arrangement By Share-Based Payment Award, Outstanding, Weighted Average Remaining Contractual Term | ' |
Weighted average remaining contractual life (Years), Outstanding | '1 year 5 months 5 days |
Weighted average remaining contractual life (Years), Granted | '2 years |
Weighted average remaining contractual life (Years), Outstanding | '1 year 6 months 22 days |
Weighted average remaining contractual life (Years), Exercisable | '1 year 6 months 22 days |
Aggregate intrinsic value, Outstanding | 479,378,600 |
Aggregate intrinsic value, Outstanding | 403,082,000 |
Aggregate intrinsic value, Exercisable | $403,082,000 |
Stock_Options_and_Warrants_Det2
Stock Options and Warrants (Details Textual) (USD $) | 3 Months Ended | 6 Months Ended | 78 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 78 Months Ended | 6 Months Ended | ||||||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Apr. 05, 2009 | |
Warrants | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Warrants | Warrants | Equity Incentive Plan 2010 [Member] | Incentive Stock Options Plan 2009 [Member] | |||||||
Minimum | Maximum | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of stock options shares permits for grant | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 45,000,000 | 2,000,000 |
Term of incentive stock option granted | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' |
Percentage of combined voting power | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10.00% | ' |
Total share-based compensation expense | $105,250 | ' | $105,250 | ' | $105,250 | ' | ' | $229,000 | $138,000 | $255,000 | $214,000 | $6,591,000 | ' | ' | ' | ' |
Unamortized compensation cost expected to be recognized | ' | ' | ' | ' | ' | ' | ' | 8,000 | ' | 8,000 | ' | 8,000 | ' | ' | ' | ' |
Class A common stock issued to each warrant holder | 1,025,000 | ' | 1,025,000 | ' | 1,025,000 | ' | 848,084 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock, par value | $0.00 | ' | $0.00 | ' | $0.00 | ' | $0.00 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock purchase warrant exercisable price | $1 | ' | $1 | ' | $1 | ' | ' | ' | ' | ' | ' | ' | $0.39 | $0.53 | ' | ' |
Proceeds from exercise of warrants | ' | ' | 1,025,000 | ' | ' | ' | 400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Series B, Series C, and Series D common share purchase warrants | ' | ' | ' | ' | ' | ' | 2,223,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Deemed dividend | $1,979,706 | ' | $1,979,706 | $211,802 | $2,257,194 | ' | $1,880,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Series B, Series C, and Series D common share price | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.50 | $1.50 | ' | ' |
Equity_Transactions_Details_Te
Equity Transactions (Details Textual) (USD $) | Dec. 31, 2013 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Sep. 04, 2013 | Jun. 30, 2013 | Dec. 31, 2013 | Sep. 17, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Oct. 17, 2013 | Sep. 04, 2013 | Sep. 04, 2013 | Sep. 04, 2013 | Oct. 25, 2013 | Dec. 31, 2013 | Jun. 30, 2013 | Sep. 04, 2013 | Sep. 04, 2013 | Dec. 31, 2013 | Dec. 17, 2013 | Dec. 31, 2013 | Dec. 31, 2013 |
Warrants | Warrants | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Restricted Stock [Member] | Formatech [Member] | Aspire Capital Fund Llc [Member] | Aspire Capital Fund Llc [Member] | Aspire Capital Fund Llc [Member] | Aspire Capital Fund Llc [Member] | Aspire Capital Fund Llc [Member] | Polymedix Inc And Polymedix Pharmaceuticals Inc [Member] | Polymedix Inc And Polymedix Pharmaceuticals Inc [Member] | Consultant [Member] | Consultant [Member] | Employee Stock Option [Member] | Restricted Stock [Member] | |||
Minimum | Maximum | Warrants | Warrants | Warrants | Warrants | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | |||||||||
Minimum | Maximum | Common Stock Purchase Agreement [Member] | Common Stock Purchase Agreement [Member] | 20 Million Common Stock Purchase Agreement [Member] | 10 Million Common Stock Purchase Agreement [Member] | 10 Million Common Stock Purchase Agreement [Member] | ||||||||||||||||||
Subsequent Event [Member] | ||||||||||||||||||||||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock, shares issued | ' | ' | ' | ' | 105,877,129 | 1,400,000 | 100,456,068 | 848,084 | 1,025,000 | ' | ' | 35,000 | 1,400,000 | 1,400,000 | 1,400,000 | ' | ' | ' | 1,400,000 | 1,400,000 | 5,000 | 50,000 | 60,000 | ' |
Common stock shares committed to purchase value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $20,000,000 | $10,000,000 | ' | ' | ' | ' | ' | ' | ' |
Term of agreements | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '36 months | ' | ' | ' | ' | ' | ' | ' | ' |
Shares issued as commitment fee (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 210,523 | ' | ' | ' | ' | ' | ' | ' | ' |
Number of common stock shares sold | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 3,204,537 | 2,712,208 | ' | ' | ' | ' | ' | ' |
Value of common stock shares sold | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,000,000 | 5,618,000 | 4,383,000 | ' | ' | ' | ' | ' | ' |
Shares issued as commitment fee | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 373,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Description of purchase agreement | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'Under the Purchase Agreement, on any trading day selected by Cellceutix which the closing sale price of our Class A Common Stock exceeds $0.25 per share, we may direct Aspire Capital to purchase up to 200,000 shares of our Class A Common Stock per trading day. The Purchase Price of such shares is equal to the lesser of a) the lowest sale price of our Class A Common Stock on the purchase date; or b) the arithmetic average of the three lowest closing sale prices for our Class A Common Stock during the twelve consecutive trading days ending on the trading day immediately preceding the purchase date. |
Description of purchase notice | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'On any date on which we submit a Purchase Notice to Aspire Capital for purchase of at least 100,000 Purchase Shares and the closing sale price of our stock is equal to or greater than $0.50 per share, we also have the right to direct Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the our Class A Common Stock traded on the OTC Bulletin Board on the next trading day, subject to the VWAP Purchase Share Volume Maximum and the VWAP Minimum Price Threshold, which is equal to the greater of (a) 90% of the closing price of our Class A Common Stock on the business day immediately preceding the VWAP Purchase Date or (b) such higher price as set forth by the Company in the VWAP Purchase Notice. The VWAP Purchase Price of such shares is the lower of (a) the Closing Sale Price on the VWAP Purchase Date; or 95% of the volume-weighted average price for our Class A Common Stock traded on the OTC Bulletin Board; and (b)on the VWAP Purchase Date, if the aggregate shares to be purchased on that date have not exceeded the VWAP Purchase Share Volume Maximum or during that portion of the VWAP Purchase Date until such time as the sooner to occur of (i) the time at which the aggregate shares traded on the OTC Bulletin Board exceed the VWAP Purchase Share Volume Maximum or (ii) the time at which the sale price of our Class A Common Stock falls below the VWAP Minimum Price Threshold. |
Common stock, par value | $0.00 | ' | ' | ' | $0.00 | ' | ' | $0 | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0 | $0 | $0 | ' |
Common Stock, Value | ' | ' | ' | ' | 10,588 | ' | ' | 400,000 | 1,025,000 | ' | ' | 70,000 | ' | ' | ' | ' | ' | ' | ' | ' | 9,000 | 105,000 | 96,000 | ' |
Common stock purchase warrant exercisable price | $1 | ' | $0.39 | $0.53 | ' | ' | ' | ' | $1 | $0 | $1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock Subscription Receivable | ' | ' | ' | ' | ' | ' | ' | 400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common stock, vested | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 35,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock based compensation | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $70,000 |
Subsequent_Events_Details_Text
Subsequent Events (Details Textual) (USD $) | 1 Months Ended | 6 Months Ended | 6 Months Ended | 1 Months Ended | 1 Months Ended | ||||||
Dec. 29, 2010 | Dec. 31, 2013 | Jun. 30, 2013 | Dec. 31, 2013 | Jun. 30, 2013 | Dec. 31, 2013 | Sep. 17, 2013 | Dec. 31, 2013 | Jan. 23, 2014 | Jan. 03, 2014 | Jan. 31, 2014 | |
Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Common Class A [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | ||||
Warrants | Warrants | Consultant [Member] | Warrants | Common Class A [Member] | |||||||
Huang Min Chung [Member] | Common Stock Purchase Agreement [Member] | ||||||||||
Aspire Capital Fund Llc [Member] | |||||||||||
Subsequent Event [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Executive's annual salary current | ' | $423,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of annual increase in salary | 10.00% | 10.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Executive's annual salary increased | ' | ' | ' | ' | ' | ' | ' | 465,850 | ' | ' | ' |
Amount of additional proceeds | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $532,000 |
Number of common shares sold | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 300,000 |
Number of stock warrants authorized to Exercise | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' |
Series B, Series C, and Series D common share purchase warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,223,000 | ' |
Common stock, par value | ' | $0.00 | ' | $0.00 | ' | $0 | $0 | ' | ' | $0.00 | ' |
Restricted common stock | ' | ' | ' | 300,000,000 | 300,000,000 | ' | ' | ' | 25,000 | ' | ' |
Granted | ' | ' | ' | ' | ' | ' | ' | ' | 100,000 | ' | ' |
Exercisable at December 31, 2013 | ' | 39,137,500 | ' | ' | ' | ' | ' | ' | 25,000 | ' | ' |
Exercisable at December 31, 2013 | ' | $0.14 | ' | ' | ' | ' | ' | ' | $1.79 | ' | ' |
Option life | ' | '7 years 5 months 19 days | ' | ' | ' | ' | ' | ' | '3 years | ' | ' |